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 A comprehensive understanding of the molecular signaling pathways that 
regulate cell growth and proliferation is essential in the realization of new 
therapeutic options to facilitate early detection and eradication of malignancy.  
Understanding the transcriptional regulation of the YPEL3 and FHIT genes forms 
the basis of this dissertation.  YPEL3, or Yippee-like 3, is a newly identified p53 
target gene that inhibits tumor cell growth and is thus itself, a novel tumor 
suppressor gene.  FHIT, or Fragile histidine triad, is a well known tumor suppressor 
gene and is regulated at the transcriptional level by another growth inhibitory 
protein, FOXO3a, a Forkhead box transcription factor. 
  Our laboratory has determined that YPEL3 is a direct transcriptional target of 
the tumor suppressor gene p53.  The first section of this dissertation provides 
significant experimental evidence to validate this observation.  Briefly, YPEL3 was 
shown to be upregulated downstream of p53 protein stabilization in a microarray 
screen that explored global gene expression modulation after RNAi-mediated 




by treatment with DNA-damaging agents resulted in stabilization of p53 protein 
along with elevation of YPEL3 transcript and protein levels.  Moreover, there exists 
a cis-acting p53 response element within the YPEL3 promoter that is bound by p53 
in response to this stress.  YPEL3 also elicits growth inhibition and decreases in 
colony formation when expressed in tumor cells.  It is apparent that cells which 
express exogenous YPEL3 are forced into a permanent cell cycle arrest, termed 
“premature senescence.”  Similar growth suppressive phenotypes are typical of 
many other known p53 target genes.  However, most of these genes are associated 
with the regulation of transient inhibition of cell division or the induction of 
apoptosis.  YPEL3 is unique in its ability to trigger premature cellular senescence.  
Indeed, YPEL3 stands out among many other p53 targets because it is among the 
first to play a role in this process.   
  To further understand the mechanism of YPEL3-induced senescence, the 
second portion of this dissertation focuses on the generation of a three-dimensional 
model of YPEL3’s protein structure.  It was hypothesized that predicting YPEL3’s 
protein structure may also aid in understanding the molecular events involved in the 
induction and maintenance of premature senescence.  Identifying structural 
homology between a predicted model of YPEL3 and other known structures may 
provide new insights into this process.  This would especially be the case if 
homology existed between the predicted structure of YPEL3 and other proteins that 
have established functions in stress-responsive or senescence-associated molecular 
pathways.  By using two independent structural prediction algorithms (Rosetta ab 




the YPEL3 protein which has significant structural homology to a family of 
Methionine oxidoreductases.  These enzymes catalyze redox-mediated antioxidant 
reactions which dissipate intracellular reactive oxygen species (ROS) through the 
repair of proteins damaged by ROX-mediated methionine to methionine sulfoxide 
oxidation.  It is even plausible that YPEL3 could be involved in the mediation of 
cellular senescence in response to severe oxidative stress.  If this is the case, the 
implications of this speculation, linking the oxidative stress response to YPEL3-
dependent cellular senescence, are indeed profound.  YPEL3 may not only play a 
role in the molecular biology of cancer but also may be involved in the cellular 
oxidative stress response as it relates to senescence and aging.        
  In the third part of this dissertation, FHIT, a tumor suppressor gene often 
deleted in epithelial-derived tumors, was also initially postulated to be regulated by 
p53 (just as in the case of YPEL3).  However, FHIT gene expression was instead 
found to be modulated by FOXO3a.  This gene’s expression was induced 
coincidentally under similar conditions as p53 such as cell cycle arrest.  FHIT is 
suppressed by the AKT/PI3K pathway upon growth factor-dependent stimulation.  
These protooncogenic kinases phosphorylate and, thereby prevent FOXO3a from 
entering the nucleus and activating FHIT gene expression.  Thus, FOXO3a is only 
able to enter the nucleus in the absence of mitogenic stimulation.  FHIT transcript 
levels are elevated in response to the removal of mitogen-containing serum from 
breast, colon carcinoma, and immortalized mammary epithelial cells.  Induction of 
FHIT gene expression is dependent on decreased PI3K kinase activity and 




factor stimulation.  As such, quiescence-dependent elevation of FHIT mRNA can 
be elicited independently of mitogen removal, by treatment with PI3K inhibitors, or 
attenuated by ectopic expression of constitutively active AKT during serum 
deprivation.  Furthermore, ectopic expression of FOXO transcription factors result 
in the upregulation of FHIT mRNA and protein levels.  Additionally, nuclear 
shuttling experiments with a FOXO3a-estrogen receptor fusion protein have 
demonstrated that FOXO must enter the nucleus to modulate expression of FHIT.  
Finally, experiments using shRNA targeting FOXO3a have revealed that the 
modulation of FHIT gene expression, downstream of PI3K inactivation, is 
dependent on endogenous FOXO3a.  
   In summary, this project began with investigating the regulation of two 
genes derived from a microarray screen to search for new p53 targets.  Validation of 
YPEL3 as a novel p53 target gene was very straightforward.  All assays employed 
in characterizing YPEL3 revealed that it behaved exactly as a classic p53 
transcriptional target.  The latter of the two genes, FHIT, however was determined 
not to be a p53 target but rather a transcriptional target of FOXO3a—another tumor 
suppressive transcription factor.  It is the hope of the author that this information 
will serve to enhance our basic understanding of the paradoxically both, 
overwhelmingly complex and elegantly simple molecular dynamics of gene 
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YPEL3: a new p53 target gene that can induce cellular 
senescence in tumor cells.  
 
INTRODUCTION TO PART 1 
The p53 tumor Suppressor Gene  
 p53 is a tumor suppressor gene that encodes a transcription factor as its protein 
product.  Transcriptional target genes of p53 regulate an exhaustive list of cellular 
signaling pathways and metabolic processes vital to maintaining cellular and organismal 
homeostasis and survival. These include control of cell division, apoptosis, senescence, 
DNA repair, angiogenesis, glycolysis, autophagy, and mitochondrial respiration 
(Vousden,K.H. and Prives,C. 2009).   
Regulation of p53 function by Mdm2 and MdmX 
p53 is primarily controlled at the post-translational level, by two negative 
regulators: Murine Double Mutant 2 (Mdm2) and Murine Double Mutant 4 or MdmX1
                                                 
1
  The "M" in the acronyms, Mdm2 and MdmX refers to "murine" and can be replaced with "H" to denote the 
human homologues, Hdm2 and HdmX, respectively.     
 
(Clegg,H.V., Itahana,K., et al. 2008, Danovi,D., Meulmeester,E., et al. 2004, Hu,B., 
Gilkes,D.M., et al. 2007, Klein,C. and Vassilev,L.T. 2004, Meulmeester,E. and 
Jochemsen,A.G. 2008, Toledo,F. and Wahl,G.M. 2006, Toledo,F. and Wahl,G.M. 2007).  
Both of these proteins can bind to the p53 protein and block its ability to interact with 




Vousden,K.H. and Prives,C. 2009).  Mdm2 is an E3 ubiquitin ligase.  As such, it can 
attach ubiquitin moieties to p53 protein and target it to the 26S proteosome for 
degradation (Clegg,H.V., Itahana,K., et al. 2008).  In an unstressed cell, p53 protein levels 
and transactivity are kept low and inactive, respectively as a result of the constitutive 
proteosomic turnover afforded by Mdm2 (Kruse,J.P. and Gu,W. 2009).  If the cell is 
exposed to a genomic insult such as a DNA-damaging agent in the form of ultraviolet 
light, environmental carcinogen, chemotherapeutic drug or ionizing radiation, the p53 
protein will be stabilized (Kruse,J.P. and Gu,W. 2009).   Elevation of intracellular p53 
protein concentrations and subsequent transactivation of downstream target genes occur 
as a result of signaling by upstream DNA damage sensing complexes2 which activate 
PIP3-type kinases ATM and ATR3
 To further refine this process, post-translational modifications of p53 play key roles 
in determining which types of target gene promoters are activated and to what degree.  As 
an example, whether p53 transactivates pro-apoptotic genes versus cell cycle arrest and 
.  These kinases, once activated can lead to the 
inhibition of Mdm2/X-mediated attenuation of p53 function through modulation of Chk1 
and Chk2 phosphorylation (Bartek,J., Bartkova,J., et al. 2007, Jazayeri,A., Falck,J., et al. 
2006, Roos,W.P. and Kaina,B. 2006).    The Chk protein kinase family is able to in turn 
phosphorylate Mdm2, MdmX and p53 (Chen,Y. and Poon,R.Y. 2008, Bartek,J., 
Bartkova,J., et al. 2007).  This allows p53 to be released from the inhibitory effects 
imposed by Mdm2 and MdmX and facilitates the transcriptional regulation of its 
downstream target genes.   
                                                 
2
  Damage sensing complexes include the RAD911 complex as well as single stranded DNA binding proteins such as replication 
protein A (RPA) that will bind at stalled replication forks associated with damaged regions of pre-replicated DNA ( Pandita,T.K.,et al 2006).    
3
  Ataxia telangiectasia mutated (ATM) and ataxia telangiectasia and Rad3 related (ATR) are serine / threonine protein 
kinases belonging to the class IV PI 3-kinase family.  They function in the detection of DNA damage as a result of genotoxic events and facilitated the 





repair targets is determined in part by phosphorlyation of different key serine residues 
including S46 located in the N-terminal transactivation domain of p53 (Vousden,K.H. and 
Prives,C. 2009) 
  In addition to DNA damage, p53 is also activated by perturbations in oncogene 
activity.  Surprisingly, p53’s ability to detect oncogene overexpression is thought 
currently to be even more important to its tumor suppressive function than its activation 
downstream of DNA damage-induced cellular stress.  In support of this, many recent 
independent studies have been conducted which have shown the initial activation of p53 
by genotoxic stressors to not be as imperative as was previously assumed for the 
prevention of cancer (Vousden,K.H. and Prives,C. 2009).           
 Once active, p53 will begin to drive the transcriptional expression of a myriad of 
transcriptional target genes.4  Extensively studied downstream effector genes include 
those that regulate cell cycle arrest such as p21—a cyclin dependent kinase inhibitor that 
inhibits cell division by blocking cyclin D1/D2/E CDK2/4 complexes from 
phosphorylating retinoblastoma (Rb) protein.  This prevents Rb, another key tumor 
suppressor gene important in cell cycle regulation, from releasing pro-proliferative E2F 
transcription factors from transcription inhibition (Abbas,T. and Dutta,A. 2009, 
Gartel,A.L. 2007).  Without this transcriptional repression, E2F-1 becomes an “oncogene 
by proxy5
                                                 
4 p53 can act as both an activator and repressor of transcription.   
” through loss of Rb, and as such, would become constitutively activated to 
induce the transcription of genes important for stimulating cell division— leading to 
tumor formation.  p53 also increases the expression of genes involved in DNA repair 




such as GADD45a (el-Deiry,W.S. 1998).  If the cell is not able to repair this damage, it is 
currently thought that there are two alternatives.  Genes that regulate apoptosis may be 
upregulated by p53 as a result of a post-translationally-mediated switch in p53 binding 
affinity for apoptotic gene promoters such as BAX, PUMA and APAF- 16
Target genes regulated by p53 intercede in the pathogenesis of cancer. 
 This will elicit 
a programmed cell death response to eliminate any tumorigenic threat posed by this pre-
cancerous cell (el-Deiry,W.S. 1998)  Another alternative, rather than apoptosis is that the 
cell may enter an irreversible form of cell cycle arrest termed premature senescence.  
p53-dependent senescence is activated by many of the same mechanisms that trigger 
transient cell cycle arrests or apoptosis, such as pathologic oncogene activation, DNA 
damage or telomere dysfunction (Vousden,K.H. and Prives,C. 2009).  It was originally 
assumed from earlier studies, that after cellular senescence was triggered in a 
premalignant cell, the permanent retention of this senescent, but still precancerous cell 
occurred in vivo based on in vitro observations.  The risk of neoplastic progression was 
thought never to be completely eliminated in this case because of the preservation of 
these diseased cells rather than apoptotic elimination.   It was recently discovered, 
however, that senescent cells do not remain stable in vivo as they do in cell culture.  
Rather, these cells apparently secrete inflammatory cytokines that result in their clearance 
by the innate immune system (Xue,W., Zender,L., et al. 2007).   
  One of p53’s most important functions7
                                                 
6
  BAX PUMA and APAF-1 (Apoptotic peptidase activating factor 1) are transcriptional target genes of p53 that commit the cell 
to apoptosis by regulating caspase cleavage, apoptosome formation and mitochondrial permeability of cytochrome C (el-Deiry,W.S. 1998,  Roos,W.P. 
2006).    
 is as a tumor suppressor—preventing 
7
The p53 protein's involvement in cancer is by far the most well studied aspects of p53, however evolutionarily speaking,  the initial biological function 
of p53 may have actually been in embryonic development.  (personal communication: Arnold Levine, keynote speaker, 2008 International p53 Conference.  




genomic mutations from becoming permanently integrated into the genome by activating 
DNA repair pathways.  As previously alluded, even in the event that stable mutations 
accumulate, resulting in aberrant oncogene activation or loss of heterozygosity of a tumor 
suppressor gene, a second line of defense exists against oncogenesis.  This innate 
protection orchestrated by p53 leads to the expression of target gene effectors involved in 
mediating either transient inhibition of cell division with DNA repair, apoptosis or 
senescence.  Expression of genes that regulate these processes is maintained in a balanced 
equilibrium by p53 to above all, maintain genomic integrity.  Thus, if irreparable genetic 
damage exists, this equilibrium will shift from expression of genes responsible for 
transient arrest and DNA repair and the cell will be forced to take more drastic measures 
to avoid incorporation of genetic aberrations.  Apoptotic or senescent induction occurs in 
this case to remove any further threat of the host cell losing its ability to “self-regulate” 
its own replication, and thus prevent carcinogenesis from occurring (Kruse,J.P. and 
Gu,W. 2009, Meulmeester,E. and Jochemsen,A.G. 2008, Riley,T., Sontag,E., et al. 2008, 
Vousden,K.H. and Prives,C. 2009).    
 So what if p53 or one of its many transducers or effectors is not functioning 
properly or is completely absent?  If the faulty or missing gene is at the lower end of the 
p53 signaling transduction spectrum such as at the level of target gene or effector, genetic 
redundancy typically observed at this level of regulation usually ensures that cellular 
homeostasis is still adequately maintained.  However, if the malfunction is at a higher 
level of regulation or even within p53 itself incurring a disruptive mutation, future 
genetic aberrancies that eventually accrue may go unnoticed by these faulty p53-




accounted for and repaired but permitted to accumulate.  Additionally, the cell will be at 
further risk of undergoing oncogenesis if it is unable to respond to anomalous oncogene 
activation (i.e. Oncogenic RAS) via p53-mediated premature senescence pathways.   
 Following the logic of P.C. Nowell’s clonal tumor cell evolution hypothesis 
(Nowell,P.C. 1976), mutant phenotypes derived from chance genetic mutations that are, 
in themselves advantageous to the cell by perpetuating cellular growth and deregulated 
proliferation, are placed under positive selection.  Certainly, advantageous mutations 
characteristic of a cancerous cell would include those that contribute to oncogene 
overexpression or tumor suppressor loss and as a consequence, loss of control over the 
cell cycle and eventual tumor formation (see illustration in Figure 20) (Kemp,C.J. 2005, 
O'Neil,N. and Rose,A. 2006, Pfeifer,G.P. and Besaratinia,A. 2009, Sidransky,D., 
Mikkelsen,T., et al. 1992).   
 Indeed, because p53 is such a pivotal component in the cells molecular arsenal 
against the development of cancer, functional loss of this gene cannot be tolerated.  Many 
malignant tumors contain loss or gain of function mutations in both p53 alleles (~50% of 
human tumors) which contribute to tumorigenesis.  Other cancers have faulty regulatory 
or effector pathways up or downstream of p53, respectively, that impede p53’s ability to 
perform its tumor suppressive function (Rayburn,E.R., Ezell,S.J., et al. 2009, Sanchez-
Beato,M., Sanchez-Aguilera,A., et al. 2003).  Therefore screening for new transcriptional 
target genes regulated by p53 is justified to further understand how p53 prevents the 




Introduction to Yippee-like 3  
       
   Yippee-like 3 (YPEL3) belongs to a five member family of closely related 
paralogues—YPEL1-5 that are named in reference to their orthologue—Drosophila 
Yippee (Hosono,K., Sasaki,T., et al. 2004a).  The Drosophila protein was first identified 
in a yeast two hybrid screen for gene products that interacted with Hemolin protein from 
Hyalophora cecropia (silk moth) (Roxstrom-Lindquist,K. and Faye,I. 2001).  Drosophila 
Yippee is suspected to contain a putative metal binding site composed of four cysteines 
which could coordinate a metal ion such as zinc and form a zinc finger motif.    Yippee 
was also found to have 76% amino acid identity with a human cDNA clone which was 
later identified as hYPEL5.  Additionally, both of these proteins are identical with respect 
to two pairs of cysteines suspected to form the zinc finger (Roxstrom-Lindquist,K. and 
Faye,I. 2001).  In addition, molecular phylogenetic analysis of all five members of the 
human Yippee family has revealed a high degree of conservation throughout eukaryotic 
evolution.  Homology extends across a broad spectrum of orthologous and paralogous 
Metazoan amino acid sequences.  For example, significant homology can even be 
identified when comparing loci from mammalian lineages to those of Mycetazoa (slime 
molds) (Baldauf,S.L. and Doolittle,W.F. 1997)(Roxstrom-Lindquist,K. and Faye,I. 2001).  
This is an indication that the Yippee gene family may be involved in molecular and 
cellular functions that are vitally important to the survival and fundamental physiological 
regulation of the eukaryotic cell (Roxstrom-Lindquist,K. and Faye,I. 2001).    
Clues toward understanding YPEL3’s biological function 




function in mice was published.  This was the first and only report (until 2010) that has 
detailed the biological function of this gene’s protein product.   It was demonstrated here 
that YPEL3 expression was upregulated in differentiating murine myeloid precursor 
(MMP) cells as they progressed toward apoptosis; it was also observed that ectopic 
expression of YPEL3 was associated with the induction of cell growth inhibition and 
apoptosis in these same cells (Baker,S.J. 2003).   
 Briefly, while searching for genes that might be involved in terminal 
differentiation and apoptosis of MMP cells using microarray technology—mYPEL3 
(referred to in the manuscript as Small Unstable Apoptotic Protein or SUAP) gene 
expression was observed to increase in terminally differentiating MMP cells.  Removal of 
the cytokine Interleukin-3 (IL-3) from the growth media of these cells normally results in 
their differentiation into mature granulocytes followed by eventual programmed cell 
death of differentiated granulocytes.  Endogenous mYPEL3 was shown to increase in 
expression after removal of IL-3 and its upregulation temporally paralleled the entry of 
these terminally differentiated granulocytes into apoptosis.  It was later shown that when 
exogenous SUAP was introduced into this cell line using an IPTG-inducible retroviral 
system, a decrease in the ability of stable transductants to form colonies was apparent.  
Flow cytometric analysis of the SUAP-expressing cells was employed to demonstrate 
that the percentage of actively dividing cells in the mYPEL3-expressing pool was the 
same when compared to control cells, thus ruling out cell cycle arrest as a possible 
mechanism of growth suppression seen in earlier colony formation experiments.  
However, the presence of phosphatidylserine on the outer cell surface—an early marker 




ectopic mYPEL3-expressing MMP cells (Baker,S.J. 2003). 
  It should also be mentioned, that at the time of this study the human YPEL3 gene had 
not been characterized yet nor had it been named.  With the fact that it was a relatively 
small (14kDa) and unstable8 protein, found to be linked to the programmed cell death 
pathway, it was aptly named: Small Unstable Apoptotic Protein or SUAP9
 In a later study, that actually characterized all five human YPEL3 family members, 
indirect immunoflorescence using pantropic polyclonal antibodies revealed that the 
human Yippee family of proteins may localize to the nucleus, mitotic spindle apparatus 
and centrioles (Hosono,K., Sasaki,T., et al. 2004a).  However, because expression levels 
between YPEL1-4 could differ dramatically from each other and the antibody used in this 
study was pantropic—being raised against a peptide sequence occurring in all family 
members, this observation should be applied to each paralogue with caution as 
overrepresentation of one may mask others’ localization or lack of detection.  
Nonetheless, these localization studies are valuable and may indicate that the Yippee-like 
gene products could be involved in cell cycle regulation, particularly at the mitotic phase 
of the cell cycle (Hosono,K., Sasaki,T., et al. 2004a).  Additionally, based on these 
observations it has been proposed that YPELs may be involved in other biological 
processes occurring in the nucleus such as DNA replication, transcription or chromatin 
remodeling—any of which could have significant impact on the regulation of cell growth 
and division (Hosono,K., Sasaki,T., et al. 2004b).  These data further supported the initial 
 in this 
manuscript (Baker, 2003).     
                                                 
8 In this manuscript it was also reported that YPEL3 protein was very unstable and incredibly difficult to 
detect via Western blot.  
9 Although the Yippee-like 3 gene actually currently holds two aliases (YPEL3 and SUAP), it will only be 




hypothesis that YPEL3 could be involved in regulation of cell growth and proliferation.      
 Other Yippee family members such as YPEL1 have been shown to be involved in 
embryological development.  For example, YPEL1 located on chromosome 22q11.2 has 
been linked to DiGeorge Syndrome, a disease that is characterized by craniofacial 
patterning defects, cardiac abnormalities and thymic hypoplasia and genetic aberrations 
involving chromosome 22 (Farlie,P., Reid,C., et al. 2001, Shprintzen,R.J. 2008).  Further 
support for a role in development stems from the observation that YPEL1 expression is 
highly expressed on the ventral side of the embryo, including the branchial arches 
involved in craniofacial patterning and development (Farlie,P., Reid,C., et al. 2001).   In 
addition, it was observed by this same group that ectopic YPEL1 expression in fibroblasts 
caused them to transition from the spindle-shaped mesynchemal morphology typical of 
these cells, to a more flattened epithelioid shape indicating a possible role in cellular 
differentiation (Farlie,P., Reid,C., et al. 2001).   
Rationale 
 A thorough examination of the anti-tumor networks governed by p53 and their 
respective downstream effectors is vital to expanding our current understanding of the 
fundamentals of cancer biology.  To further this goal we have employed Affymetrix 
microarray technology to monitor fluctuations of the MCF-7 breast carcinoma cell line's 
transcriptome before and after stabilization of endogenous p53, to detect novel p53 
regulated genes that may be effectors of the p53 tumor suppressor response pathway.  
Briefly, MCF-7 cells expressing wildtype p53 and overexpressing both HdmX and Hdm2 




expression of these critical negative regulators.  By lowering transcript levels of HdmX 
and Hdm2, the inhibitory control over p53 by these proteins is relaxed, thus leading to the 
activation of p53’s transcriptional activity. Following data mining and statistical analysis 
of gene expression data, a list of genes upregulated after downregulation of HdmX/2 and 
subsequent stabilization of p53 protein levels, was generated.  The complete gene list can 
be obtained from Heminger et al. (Heminger,K., Markey,M., et al. 2009).   Genes 
selected for further validation as putative p53 targets included YPEL3.   
 The primary goal of part one was to validate YPEL3 as a potential transcriptional 
gene target of p53 and identify any biological functions within the realm of molecular 
regulation over neoplastic genesis or attenuation of malignant transformation by 
mechanisms such as apoptosis, cell cycle arrest or senescence.  By accomplishing this, a 
more comprehensive understanding of p53's anti-tumor pathways was gained.  
Furthermore, knowledge derived from this aim may support future translational research 
efforts to develop therapeutically viable treatment and screening options that exploit the 
potential tumor suppressive characteristics inherent in the YPEL3 protein.    
MATERIALS AND METHODS  
Plasmids and Transfections 
 Transient transfections were carried out using Lipofectamine or Lipofectamine 
2000 (Invitrogen) according to the manufacturer’s instructions, with regard to suggested 
cell plating density, DNA amounts and lipid: DNA ratios.  
 For exogenous expression of p53— pcDNA3.1-p53 was utilized in RT-PCR studies 




generous gifts from Dr. Madhavi Kadakia (Wright State University).   pcDNA3.1-
(constitutively active) caAKT and pcDNA3.1-(kinase dead) kdAKT were kind gifts from 
Dr. Lindsay Mayo (Indiana University).  The pGL3-BASIC vector (Promega) was used in 
all luciferase-based reporter assays. The synthetic luciferase reporter plasmid PG13-luc 
was used as a measure of p53 transactivation potential.  It contains 13 copies of the p53 
consensus sequence and was obtained by subcloning the promoter sequence from 
pG13CAT into pGL3-BASIC. The Gateway Viral Power Cloning System containing 
pLenti4-T/O-V5-DEST and pENTR/SD/D-TOPO vectors was purchased from 
Invitrogen.  
   The YPEL3 promoter region was identified by comparing the YPEL3 reference 
sequence (NCBI) to the YPEL3 genomic sequence from the University of California 
Santa Cruz (UCSC) genome browser.  Putative p53 consensus binding sites were located 
across a ~10,000 bp stretch upstream of the YPEL3 gene which also includes the first 
exon and intron using p53MH—a p53 binding site search algorithm (Hoh,J., Jin,S., et al. 
2002).  Three potential sites were located in a 1506 bp (-1386 to +120) region of the 
YPEL3 promoter.  This region was amplified using Platinum Pfx polymerase (Invitrogen) 
from BAC clone RP11-114A14 (BACPAC Resources Center) and subcloned into pCR-
BLUNT-II-TOPO vector using the Zero Blunt TOPO PCR Cloning Kit (Invitrogen).  The 
YPEL3 promoter element of interest was then isolated using KpnI and XhoI and 
directionally subcloned into pGL3-BASIC. Oligonucleotides possessing the p53 response 
element were synthesized, annealed and directionally cloned into pGL3-BASIC. In 
addition a triple mutant was created with critical C/G residues mutated in each of the 




All reporter constructs were confirmed by DNA sequencing analysis. 
   The tetracycline-inducible (tet-on) lentiviral YPEL3- V5-tagged expression 
construct was designed by cloning the YPEL3 ORF into pENTR/SD/D-TOPO and then 
into the pLenti4-T/O-V5 DEST vector via the Gateway cloning system (Invitrogen). 
Lenti-FOXO3a-ER TM was created by subcloning the FOXO3a-ER fusion open reading 
frame from HA-FOXO3a TM-ER into pENTR-TOPO and subsequently recombining this 
construct with plenti4 lentiviral vector using Gateway recombination technology 
(Invitrogen).  FOXO expression vectors including HA-FOXO3a TM-ER (Addgene 
plasmid 8353), FLAG-FOXO3a WT (Addgene plasmid 8360), FLAG-FOXO3a TM 
(Addgene plasmid 8361) were all kind gifts from Michael Greenburg through the 
Addgene repository (www.addgene.org)(Brunet,A., Sweeney,L.B., et al. 2004, Tran,H., 
Brunet,A., et al. 2002).   FLAG-Foxo4 (Addgene plasmid 17549) and pcDNA3 and Flag 
FKHR AAA mutant (FOXO1 TM, Addgene plasmid 13508) were generous gifts from 
Domenico Accili and Kunliang Guan, respectively (Tang,E.D., Nunez,G., et al. 1999).    
RT-PCR 
  Total RNA was isolated using the e.Z.N.A. Total RNA kit (Omega Bio-Tek) 
according to the manufacturer’s instructions.  RNA quality and quantity was assessed on 
a RNA nanochip (Agilent Technologies).  One microgram of total RNA was used as a 
template for cDNA synthesis using the reverse transcriptase core reagent kit (Applied 
Biosystems).  Taqman based PCR was performed in triplicate using Assay on Demand 
probe sets (Applied Biosystems) and an Applied Biosystems 7900 Sequence Detection 





      All cell lines were maintained at 37 degrees Celsius in a 5% carbon dioxide 
environment.  All cell lines with the exception of 76ntert and MCF10A cells were grown 
in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with either 10% fetal 
bovine serum (FBS) or 10% neonatal calf serum (NCS) and 50 µg/ml gentamycin sulfate.  
MCF10A and 76Ntert immortalized mammary epithelial cells were grown in Mammary 
Epithelial Growth Medium (Lonza) supplemented with a Clonetics MEGM BulletKit 
containing the following supplements: recombinant epidermal growth factor (rEGF), 
insulin, 50 µg / ml gentamycin, bovine pituitary extract (BPE), hydrocortisone and 100 
ng/ml Cholera toxin. Each BulletKit contained pre-aliquoted amounts of each supplement 
that would establish 1X concentrations after dilution in 500 ml of MEGM base media.    
 H1299 cells were derived from non-small-cell lung carcinoma devoid of p53 and 
have undetectable levels of p63γ.  U2OS osteosarcoma cells and MCF7 breast carcinoma 
cells all express wild-type p53.  In addition, MCF7 cells express high levels of Hdm2 and 
HdmX.  HCT116 +/+ and -/- p53 colon carcinoma cell lines are isogenic with the 
exception of p53 status.  SAOS-2 cells were derived from an osteosarcoma and are a p53 
null cell line.  MCF10A cells are immortalized mammary epithelial cells derived from 
human breast reductions.  All of these tumor lines were purchased from the American 
Type Culture Collection.  76ntert immortalized mammary epithelial cells also express 
wild-type p53 and were a generous gift from Dr. Vilma Band (University of Nebraska). 
Reporter Assays 




cotransfection of YPEL3-luc (250 ng), Renilla-luc (2.5-15 ng) and respective 
overexpression vector (10 ng – 1 µg). The following day, cells were lysed on the plate 
using 1X passive lysis buffer (Promega) and analyzed by Dual Luciferase Assay Kit 
(Promega) according to the manufacturer’s instructions.  All experiments for each 
treatment were performed in triplicate.  Error bars show variation as the standard 
deviation of each set of biological triplicates.  Statistical significance was determined by 
using the paired student’s t-test (Sigma Plot). 
DNA Damage Experiments 
 Twenty-four hours prior to treatment with Bleomycin, 76ntert immortalized 
mammary epithelial cells were seeded at a density of 150k cells/6cm plate. The following 
day the plates were treated with increasing doses of Bleomycin. Twenty-four hours later 
cells were harvested. HCT116 cells either containing wildtype p53 or that were p53-null 
were plated at 200k cells/6 cm plate.  Twenty-four hours after plating, cells were treated 
with 0.5 µg/mL Doxorubicin and harvested at 0 hr, 2 hr, 6 hr and 24 hours post-treatment.  
MCF7 cells were plated at 250k cells/6cm plate.  Cells were irradiated with 0 or 500 J/m² 
UVC (Stratalinker). Twenty-four hours after irradiation cells were harvested. Total RNA 
was extracted from the harvested cells and gene expression analyzed by RT-PCR. 
Lentiviral Production and Colony Formation Assay 
Lentiviral vectors were produced by cotransfection of 293FT cells with pLentiYPEL3 
and lentiviral packaging mix (Invitrogen) according to the manufacturer’s 
instructions.  Lentivirus-containing supernatant was harvested at 48 hours after 




containing Tetracycline Repressor (100,000 cells/well) were transduced with Lenti-
YPEL3 or left untreated and were incubated in complete medium for 24 hours. 
Infections were carried overnight in the presence of 4 µg/mL Polybrene (Sigma).   
Following infection, cells were treated with tetracycline for 14 days and then stained 
with 40% methanol /1% crystal violet stain.    
MCF10A Transformation-Colony Formation Assay 
 
             MCF10A immortalized mammary epithelial cells were reverse-infected overnight 
by plating 200K cells in 6-well plates 8 µg/ml polybrene and differing combinations of 
the following shRNA expressing lentiviruses: plenti4-shp53, plenti6-RAS, plenti6-GFP, 
misson-shYPEL3 all at MOIs of 2. Cells were permitted to grow for 4 weeks with 
complete MEG media changes every three days.  Random images were captured of each 
monolayer using an Olympus 1X70 fluorescence microscope using phase contrast on day 
5 and day 10 after infection.  After 31 days, plates were stained with 1% crystal violet/ 
70% methanol for 5 minutes followed by 6 washes with 1X PBS and then photographed.  
Senescence Associated beta-Galactosidase Staining 
 
          U2OS cells stably expressing the Tetracycline Repressor and Tetracycline inducible 
YPEL3 or LacZ were induced with 1 mg/mL Tetracycline for 6-7 days.  Cells were 
processed with the Senescence beta-Galactosidase Staining Kit, Cell Signaling 
Technology according to the manufacturer’s instructions and visualized on an Olympus 





 p53 induces an upregulation of YPEL3 gene expression. 
 
Ectopic expression of p53 induces YPEL3 gene expression.   
  
                In order to determine if YPEL3 is a direct target of p53, it is expected that an 
increase in expression would be seen in the presence of exogenous p53.  To test this, 
U2OS osteosarcoma cells were transfected with pCMV 3.1A-p53 expression vector or 
vector alone and then assessed by quantitative PCR (qPCR) 24h later. 
               U2OS cells demonstrated an increase in YPEL3 gene expression twenty-four 
hours after being transiently transfected with p53 (Figure 1A, black bars). Expression 
levels of the p53 target gene—cyclin dependent kinase inhibitor 1A (CDKN1A) or p21, 
was also monitored as an indicator for p53-depedent transactivation.  As anticipated, p21 
expression demonstrated a similar increase in expression resulting from p53 
overexpression.    
     In addition to examining the effect of p53 on YPEL3 expression, the p53 family 
of transcription factors includes other members such as p63γ and p73α10
                                                 
10 The following p63 isoforms exist: p63TA, ΔNp63, p63 α, p63 β and p63γ in mice and humans.  p73 has at 28 different isoforms (α, 
β, γ, δ, ε, ζ, η) each retaining the full length protein (TA), missing exon 2, missing exon  2/3, or missing the entire N-term 
transactivation domain, ΔN.  The TA isoforms of both proteins typically are the strongest transactivators.  The ΔN isoforms can acts as 
dominant negatives to the TAs and thus may act as oncogenes ( Murray-Zmijewski,F., et al, 2006).   
 that play roles in 
the molecular regulation of epithelial differentiation and the cellular stress response, 
respectively (Murray-Zmijewski,F., Lane,D.P., et al. 2006).  These genes encode 
transcription factors that can bind to and transactivate DNA sequences similar to the p53 




p53 target genes (Murray-Zmijewski,F., Lane,D.P., et al. 2006, Ozaki,T. and 
Nakagawara,A. 2005, Sbisa,E., Catalano,D., et al. 2007).  Therefore, it was of interest to 
determine if these proteins could activate YPEL3 gene expression.  To test this, p63γ—
the strongest transactivator of the p63 isoforms, and p73α—a p73 isoform that is 
normally induced in response to genotoxic stress (Ozaki,T. and Nakagawara,A. 2005) 
were transfected into U2OS and H1299 cells, respectively.  As anticipated from the 
results obtained with overexpression of p53, introducing p63у or p73α resulted in an 
increase in YPEL3 gene expression—further extending the scope of regulation of YPEL3 
gene expression to all three p53 family members ( Figure 1A-C).  Interestingly, based on 
this result, there may be a link between p63 regulation of epithelial differentiation and the 
YPEL family, in particular regarding YPEL1 and its role in mesynchemal to epithelial 
differentiation (see introduction and YPEL3 background section) (Candi,E., Cipollone,R., 
et al. 2008, Farlie,P., Reid,C., et al. 2001).    
YPEL3 gene expression is altered in response to genotoxic stress through activation of 
endogenous p53. 
            
The p53 protein is stabilized as a result of DNA damage-dependent genotoxic stress in 
order to facilitate cell cycle arrest and DNA repair; although apoptosis or cellular 
senescence may occur if damage is severe and sufficient repair is not achieved (el-
Deiry,W.S. 1998).  These cellular defense mechanisms governed by p53 protect the cell 
from accruing genetic mutations that could potentially increase the risk of neoplastic 
transformation (see Introduction and p53 background section for a more detailed 




damage, tumor and immortalized cell lines were treated with a range of doses of 
chemotherapeutic drugs bleomycin or doxorubicin (76nTERT mammary epithelial cells 
and HCT116 +/+ p53 colon carcinoma cells, Figure 2 and 3), UVC irradiation (MCF7 
and 76nTERT mammary epithelial cells, Figure 4) or a doxorubicin time course (HCT116 
colon carcinoma cells, wildtype and p53 null, Figure 5).  After treatment, all cell types 
were processed by RT-PCR analysis to assess YPEL3 mRNA levels as well as the 
expression levels of p21 or BAX—to genes established as transcriptional targets of p53.  
By treating 76nTERT immortalized mammary epithelial cells with increasing doses of the 
radiomimetic bleomycin, it was observed that YPEL3 mRNA increased in a dose-
dependent manner along with p21 and BAX (Figure 2, bottom panel).  HCT116 +/+ p53 
cells treated with doxorubicin demonstrated a robust dose response elevation of YPEL3 
and p21 mRNA levels (Figure 2, top panel).  Endogenous YPEL3 protein was also 
observed to increase in HCT116 cells +/+ p53 after doxorubicin treatment (Figure 3).  
Additionally, ultraviolet radiation (254nm UVC, 0-500 J/m²) elicited a similar elevation 
of YPEL3 mRNA expression in 76nTert mammary epithelial cells (Figure 4, bottom 
panel). MCF7 cells were also treated with UVC, and at a relatively high dose of 500 J / 
m² compared to doses used with 76nTert cells, only a two fold increase in YPEL3 
transcript was observed (Figure 4, top panel).  This may be because the p53 response to 
DNA damage in MCF7 cells is dampened due to the overexpressed levels of HdmX and 
Hdm2 (Heminger,K., Markey,M., et al. 2009) compared to breast epithelial cells.  
             To determine if p53 was required for the DNA damage-dependent increase in 
YPEL3 transcript, HCT116 colon carcinoma cells that are isogenic with the exception of 




At several time points, samples were collected and analyzed for YPEL3 and p21 
expression levels.  A significant temporal increase in both YPEL3 and p21 mRNA levels 
was observed in the cell line containing wildtype p53 (Figure 5, left panel).  However, the 
same cell line null for p53 demonstrated much less of an increase in YPEL3 mRNA when 
compared to the same cells expressing wildtype p53 (right panel).   p21 levels increased 
to a lesser degree in HCT116 -/- p53 cells at 2 and 6 hour time points  compared to p53-
positive cells.  However, after 24h hours of doxorubicin treatment both cell lines 
demonstrated a similar increase in p21 levels (10-fold compared to 0h time points).  It is 
possible that the five-fold induction of YPEL3 transcript levels observed in p53-null 
HCT116 cells after 24h of doxorubicin treatment may be the result of p73α upregulation 
in response to DNA damage (Fernandez-Garcia,B., Vaque,J.P., et al. 2007).  Furthermore, 
endogenous p73 has been shown by other labs to be upregulated after DNA damage, in 
the same cell line used in these experiments (Lokshin,M., Tanaka,T., et al. 2005).  This 
observation coupled with the fact that p73α overexpression triggered an increase in 
YPEL3 mRNA in H1299 cells (see Figure 1C), further support a potential role for p73 in 
the regulation YPEL3 gene expression.    
Computational analysis of the YPEL3 promoter region reveals potential cis-acting p53 
response elements.  
 Computational analyses of the YPEL3 promoter for DNA sequences that 
resemble the consensus p53 binding site were performed using the publicly available  
 Figure 1. YPEL3 mRNA levels increase in response to overexpression with p53, p63 




A. U2OS cells were transfected with 125 ng of pcDNA3.1-p53 (p53) or an equivalent 
amount of pcDNA3.1A (vector). B. U2OS cells were transfected with 1 µg of pcDNA3.1-
p63g-GST. C. H1299 cells were transfected with 125 ng pcDNA3.1-p73a or an 
equivalent amount of pcDNA3.1A (vector). Cells were harvested 24 hours after 
transfection and YPEL3 and p21 RNA levels analyzed by RT-PCR using GAPDH to 
normalize against. Y-axis is the relative fold change normalized to vector-only transfected 









Figure 2. YPEL3 mRNA increases in a dose dependent manner in response to 
DNA damage.  
HCT116+/+p53 cells were exposed to increasing doses of doxorubicin (0-0.5 μg/mL) 
for 24h (top panel). 76NTert mammary epithelial cells were exposed to Bleomycin 
(0-0.1 units/mL) for 24 hours (bottom panel). YPEL3 and p21 mRNA levels were 
assayed by RT-PCR and normalized to GAPDH mRNA levels. Error bars represent 







Figure 3. Endogenous YPEL3 protein levels increase in response to DNA 
damage. 
Endogenous YPEL3 (top panel) and p53 (bottom panel) protein levels increase in 
HCT116+/+p53 cells exposed to 0.4 μg/mL doxorubicin for 40 hours (compare 
untreated (-) to doxorubicin treated (+)).  shYPEL3 represents HCT116+/+p53 cells 









p53MH algorithm (Hoh,J., Jin,S., et al. 2002).  This program uses the p53 consensus 
binding sequence (Transfac database, PMW(position weighted matrix) M273, 
RRRCA/TA/TGYYY ---0-14N--- RRRCA/TA/TGYYY) to search a DNA sequence for 
potential p53 binding sites matching the consensus binding site (el-Deiry,W.S., Kern,S.E., 
et al. 1992).   Several binding sites were located both directly adjacent to and overlapping 
the transcription start site of the gene (see Figure 6A), thus justifying further experiments 
such as luciferase reporter analysis and chromatin immunoprecipitation of this region of 
the YPEL3 promoter for p53 binding.  Using this algorithm, another site with 80% 
homology to the p53 consensus was also found ~1400 base pairs 5ʹ of the transcription 
start site.  Shortly after identification of these potential p53 binding sites, a database, p53 
FamTaG, containing an in silico global promoter map of all known human genes 
containing potential p53 response elements coupled to microarray data containing p53, 
p63 and p73 overexpression-mediated gene expression modulations of the human 
transcriptome was published online (Sbisa,E., Catalano,D., et al. 2007).  YPEL3 was 
included in the database under genes that were found to be elevated as a result of the 
overexpression of p53 and p63—supporting data reported in Figure 1.  In addition, two 
p53 response elements were listed in the in silico database; however, ChIP primers 
(Figure 12) that I designed to target each site failed to demonstrate that p53 actually 
interacted with either of the two (computationally determined) response elements (data 
not shown).      
Reporter Analysis of the YPEL3 promoter.   A 1506 bp region of the YPEL3 promoter 
region including both potential p53 binding regions was cloned using a BAC clone 




  Figure 4. YPEL3 mRNA increases in response to UVC irradiation.  
MCF7 cells were treated without and with 500 J / m² UVC radiation (top panel). 76nTert 
mammary epithelial cells were irradiated with increasing doses of UVC (0, 25, 50, 250, 
500 J / m²) (bottom panel). Twenty-four hours following irradiation, YPEL3 and p21 








Figure 5. The DNA damage-dependent increase in YPEL3 mRNA expression is p53 
dependent in HCT116 colon carcinoma cells.   
  (A) HCT116 +/+ p53 and (B) HCT116 -/- p53 were exposed to 0.5 μg/mL of 
doxorubicin and total RNA extracted at the indicated time point. YPEL3 (black bars) and 
p21 (grey bars) mRNA levels were assayed by RT-PCR. All gene expression values were 
normalized to GAPDH expression.  Error bars represent 95% confidence intervals.  (C) 
Western blot analysis of p53 protein levels following a treatment with 0.5 μg/mL of 
doxorubicin for the indicated time points.  As expected Hct116+/+ p53 cells show a 









of chromosome 16 including the YPEL3 gene and 5ʹ region upstream as a PCR template. 
This region was cloned into the PGL3-Basic luciferase reporter construct, effectively 
placing the luciferase gene under transcriptional control by the 1506 base pair region of 
the YPEL3 promoter (Figure 6A). The YPEL3 1506 bp reporter construct was tested in 
the presence of exogenous p53 for activity by cotransfection into p53-null cell lines 
(H1299 and HCT116-/- p53) with pCMV3.1A-p53.  An increase in relative luciferase 
activity was observed with increasing amounts of p53 in both cell lines (Figure 6B).  
PG13-luc, a synthetic p53-responsive reporter harboring thirteen p53 consensus-binding 
sites was used as a positive control to indicate that p53 transactivation occurred.   
              As previously alluded to, it has been established in the literature that p53 family 
members such as p63γ can also transactivate known p53 transcriptional targets (Murray-
Zmijewski,F., Lane,D.P., et al. 2006).  Therefore, YPEL3 promoter driven-luciferase 
activity was examine in the presence of overexpressed p63γ.  Indeed, a significant 
increase in luciferase activity was observed with increasing amounts of p63γ expression 
vector cotransfected into H1299 cells (Figure 7).  Furthermore, p63γ overexpression is 
not cytotoxic at high doses compared to p53.  Thus, ten times more p63γ vector was able 
to be transfected into cells than p53 to elicit a robust >70 fold increase in luciferase 
activity after 24h.   This finding provides support for previous observations that p63 
overexpression leads to the induction of endogenous YPEL3 expression (see Figure 3B).   
                 To determine the contribution of each binding site in response to exogenous 
p53, a deletion analysis was performed whereby truncation mutants of the 1506 bp-




Two deletion mutant reporters were cloned. They are referred to as the “5ʹ-deletion 
mutant” and “3ʹ-deletion mutant”—denoting that the 5ʹ or 3ʹ terminus of the YPEL3 
promoter was removed from each, respectively (Figure 8, top panel).  Each of these 
reporters was cotransfected with p53 (center panel) or p63γ (bottom panel) expression 
vectors and cellular extracts were assayed 24h later.  From these experiments, it was 
observed that the 5´-deletion mutant retained similar luciferase induction profiles as 
wildtype in response to ectopic p53 or p63.  The 3´-deletion mutant however, lost all 
luciferase induction potential.  This was expected because it did not retain any potential 
binding sites.    Therefore, it was concluded that the 3ʹ response element (retained in the 
5ʹtruncation mutant reporter), encompassing the transcription start site was responsible 
for the elevation of luciferase activity resulting from transfection of either p53 or p63γ.  
                 The 605 bp 5-deletion mutant, containing the suspected p53-binding site was 
also tested for luciferase activity after DNA damage-dependent p53 induction.  HCT116 
colon carcinoma cells expressing p53 were transiently transfected with the YPEL3 605 
bp reporter and treated twenty-four hours later with doxorubicin.  A 2-fold elevation in 
luciferase activity was observed in response to p53 activation by DNA damage resulting 
from doxorubicin treatment (Figure 9)—indicating that this region of the YPEL3 








 Thus, this element was hypothesized to be responsible for the DNA damage-dependent 
increases in YPEL3 gene expression observed in Figures 2-5.  To further examine this 
site, a 3ʹ 50 bp response element containing all three half sites was cloned into PGL3-
Basic (Figure 10, top panel). Two additional mutant reporters were also constructed.  The 
C and G nucleotides required for p53 binding located at the 4th and 7th position of each 10 
bp half site, respectively, were changed to either A or T.   Only critical nucleotides 
necessary for p53 binding were changed while preserving the remaining sequence of the 
response element to facilitate a more conservative approach (compared to deletion 
analysis) to test p53-dependent transactivation of this site.  The second mutant construct, 
containing a scrambled 50-base pair sequence was employed as an additional negative 
control in that it should also not be able to bind p53.  All three reporters were tested by 
contransfection with increasing amounts of p53 expression plasmid into H1299 cells to 
demonstrate the preferential binding and transactivation of p53 at this potential binding 
site.  The wildtype 50 bp reporter elicited a dose-dependent response to increasing 
amounts of p53, whereas both of the mutants showed no increase in activity (Figure 10, 
bottom panel).  This result demonstrated that p53 could induce transcription dependent 
on a 50 bp region of the YPEL3 promoter containing three adjacent half-binding sites 





Figure 6. The YPEL3 promoter contains a p53 response element. 
 (A) a 1.5 kilobasepair region of the YPEL3 promoter spanning -1386 to +120 relative to 
the start site of transcription was cloned upstream of a firefly luciferase reporter gene 
(YPEL3-luc). The asterisks represent putative p53 half-sites as determined by analysis of 
the promoter sequence with the p53MH algorithm. The location of the three p53-half 
sites found searching the promoter sequence with p53MH is shown along with the 
percentage of conservation to the p53 consensus binding site.  Bolded nucleotides are 
critical to maintaining the binding affinity of the response element to p53.  (B) YPEL3-
luc activity (gray bars) and PG13-luc activity (black bars), used as a positive indicator for 
p53 transactivity were increased in H1299 (center panel) and Hct116 -/- p53 (bottom 
panel) when cotransfected with a human p53 expression vector.  Luciferase activity from 
both reporters was normalized by cotransfection with pCMV-Renilla-Luc. Each assay 








Figure 7.  p63γ can activate the YPEL3 promoter reporter gene. 
Increasing amounts of p63 γ expression vector were cotransfected with the 1506 bp 
YPEL3 luciferase reporter or vector only.  Luciferase values were determined 24h after 
transfection and normalized to CMV Renilla-luc to control for variation of transfection 







Figure 8.  Deletion analysis of the YPEL3 promoter.   
  Five and three prime deletion mutants of the 1506 bp YPEL3 promoter luciferase 
reporter were cloned by removal of segments by specific restriction digest and 
recircularization of the linearized vector. Arrows represent potential p53 binding sites 
(Top panel).  Overexpression experiments with either p53 (center panel) or p63γ (bottom 
panel) were performed to determine which deletion mutant still contained a functional 







Figure 9. The YPEL3 promoter contains a DNA-damage response element.  
A truncation of region of the YPEL3 promoter spanning -486 to +120 was subcloned 
into the pGL3-basic luciferase reporter vector.  The reporter was transfected into 
Hct116 cells harboring wild-type p53 and then subjected to DNA damage by 
doxorubicin treatment for 24 hours prior to firefly luciferase analysis. Normalization 
was performed by cotransfection with a pSV40-beta-galacosidase plasmid and 







  Figure 10. The core p53 binding region required for YPEL3 transcriptional 
activation consists of three sequential 10 bp half sites.      
A 50 bp region containing the three putative p53 half sites overlapping the YPEL3 
transcription start site was cloned into the pGL3-Basic luciferase reporter construct. 
Arrows represent each half site and gray blocks represent exons 1 and 2.  The p53 
response element is boxed and nucleotides of each half-site are in bolded and labeled 
below each respective site.  Nucleotides conserved with the p53 consensus sequence are 
capitalized (top panel, cartoon). The wild type YPEL3 50bp reporter (black bars), a 50 bp 
triple mutant where each half site harbored mutations at the critical C and G residues at 
the 4th and 7th position of each half site (grey bars) and a reporter containing a 50 bp 
scrambled sequence (white bars) were each cotransfected with renilla luciferase plasmid 
and increasing amounts of p53 plasmid.  Relative luciferase activity represents firefly 
luciferase light units over renilla luciferase light units for each sample.  Error bars 
represent standard deviation of the mean of three biological replicates.  The Western blot 
shows the level of p53 protein for each transfection.   The western blot below 
demonstrates that p53 protein expression increased with increasing amounts of plasmid 








              Caution must be exercised when deleting portions of promoter DNA from a 
luciferase reporter while attempting to identify cis-acting enhancer elements.  It is 
necessary to ensure that basal transcriptional activity of the mutated reporter gene is not 
inadvertently lost during deletion analysis—possibly yielding false positive results.  In 
other words, by deleting regulatory regions around the transcription start site of the 
YPEL3 luciferase reporter may block luciferase transcription entirely by inadvertently 
destroying the YPEL3 promoter transcription start site.   Thus loss of transactivation by 
the response element that is responsible for p53 dependent activation of YPEL3 promoter 
may only really just be the result of losing all basal reporter transcription.  In order to 
address this concern, the luciferase activity of YPEL3 50 bp-luc, YPEL3 50 bp triple 
mutant-luc, and YPEL3 1506 bp-luc (wildtype) were measured in response to p53 
overexpression and graphed relative to each other along with the empty vector—to 
provide an indication of promoterless-baseline expression ( Figure 11).  An additional 
site-directed mutant was designed, referred to as “1506 bp-luc site-directed,” where the 
4th C and 7th G of the central p53 half site were mutated to A and T, respectively.  This 
construct was also assayed in the presence of increasing amounts of p53 expression 
vector along with the other four previously discussed reporters.  As previously observed, 
both wildtype YPEL3 luciferase reporters (1506 bp-luc and wt50bp-luc) showed p53-
dependent increases in luciferase activity that paralleled the amount of p53 cotransfected 
(Figure 11).  The mutant reporters, however, did not respond to the presence of ectopic 
p53—indicating that mutated nucleotides within the suspected p53 binding site are 
indeed critical for transactivation of the YPEL3 promoter by p53.  The basal promoter 




pGL3-BASIC empty vector, albeit at a lower level when comparing each to its respective 
wildtype reporter.    
             Although luciferase reporter analysis is a powerful technique for assessing the 
transactivation potential of a particular transcription factor on a specific DNA sequence, 
it is less than perfect in that a disruption of the genomic region of DNA under scrutiny 
from its chromosomal environment occurs after cloning it into a luciferase vector.  
Transcriptional effects of other elements adjacent to the cloned region of DNA being 
analyzed are not taken into account during the analysis.  In addition, promoter regulation 
is constantly being affected by epigenetic mechanisms.  In vivo, promoter methylation 
acts to silence gene expression along with chromatin remodeling complexes which can 
modify histones and alter interactions with nuclear scaffolding (Robert Weinberg, The 
Biology of Cancer, 2006).  This can change local chromatin architecture in the vicinity of 
the promoter region—affecting the accessibility of transcription factor binding sites by 
compatible transcription factors.  The effects that these processes have on regulation of 
transcription cannot be accounted for by solely relying on luciferase reporter studies.  
Therefore, in order to explore p53 interactions with the genomic YPEL3 promoter in 
vivo, chromatin immunoprecipitation was employed.   
Endogenous p53 binds to the YPEL3 gene promoter in vivo in response to DNA 
damage.   
Chromatin immunoprecipitation or ChIP allows the investigator to probe trans-acting 
factor interactions within specific DNA regions while maintaining the genomic 




Figure 11. p53-dependent activation of the full length YPEL3 promoter is inhibited 
by site-directed mutagenesis of the central p53 half-site. 
H1299 cells were transfected with 200 ng of each luciferase reporter, 1ng of Renilla-luc 
and increasing amounts of p53 plasmid (2.5-20ng) in 24 well plates.  To demonstrate that 
each of the YPEL3 mutant reporters (1506 bp site directed mutant-luc and 50 bp-triple 
half site mutant-luc) maintained some degree of basal promoter activity, pGL3-BASIC 
empty vector is provided for comparison.  Error bars represent the standard deviation of 















sonicated chromatin (300-500 bp) was isolated from HCT116 colon carcinoma cells 
expressing wildtype p53 treated with and without doxorubicin to induce endogenous p53 
stabilization and activation. Chromatin fragments covalently complexed with p53 protein 
were isolated using a combination of anti-p53 Ab-1 antibody and protein G-coupled 
magnetic beads.  After washing and crosslink reversal, the resulting chromatin samples 
were analyzed by polymerase chain reaction (PCR).  In order to assess potential 
interactions of endogenous p53 protein with the suspected p53 binding site (see Figure 
10, top panel) present in the YPEL3 promoter region, primer pairs used in PCR were 
designed to probe this triple half-site (Firgure 12, cyan rectangle and yellow triangle) and 
several other regions with sequences that matched the p53 consensus above a threshold of 
60% (Figure 12, red triangles) throughout a 5 kb region of the YPEL3 gene and promoter 
region.    
             Consistent with earlier luciferase reporter results, ChIP analysis shows that p53 is 
bound to the YPEL3 promoter in response to DNA damage-dependent genotoxic stress 
(Figure 13).  This is evidenced by the detection of PCR product specific to primer pairs B 
using chromatin immunoprecipitated with p53 antibody from doxorubicin-treated cell 
lysate as a template for PCR amplification.  Primer pair B encompasses a region 315 base 
pairs upstream of the (3ʹ) p53 consensus site identified from luciferase-based reporter 
studies.  Primer region B was the closest region to the suspected p53 binding site that was 
non-GC rich and thus consistently compatible with PCR reaction conditions required to 
obtain a single reaction product.  To demonstrate the specificity of p53 interacting with 
this specific region of DNA adjacent to YPEL3 transcription start site, primers pairs “A” 




Figure 12. DNA regions of the YPEL3 gene examined by chromatin 
immunoprecipitation (ChIP).  
 The transcription start site is denoted by the bent arrow at the 5´end of exon 1.  All exons 
are highlighted in green.  Regions amplified by PCR in the ChIP experiment are 
highlighted by orange arrows.  Larger red triangles mark potential p53 binding sites 
reaching a threshold of at least 60% similarity to the p53 consensus binding site.  The 
smaller red triangles flanking each orange arrow (PCR product) represent individual 
primers.  Primer pair 13 and 7 correspond regions A and C, respectively which were used 
as negative controls.  Region B was amplified by primer set 4 and is located 
approximately 400 base pairs downstream from the transcription start site and p53 
binding site cluster (cyan rectangle).   A potential p53famTaG site included in the 
analysis is located in the 5’ promoter region, upstream ~1000 bp from the YPEL3 
transcriptional start site and is labeled in blue font.  It is encompassed by the negative 







 Figure 13.  In response to genotoxic stress endogenous p53 protein is able to bind 
directly to the YPEL3 promoter region in vivo. 
Chromatin immunoprecipitation assays were performed using undamaged or doxorubicin 
treated HCT116 +/+ p53 cells.  Crosslinked chromatin was immunoprecipitated with p53 
or IgG negative control antibodies.  After crosslink reversal, PCR products were 
generated from chromatin from each treatment condition (untreated and doxorubicin 
treated) using primers specific to regions A, B and C.   “In” denotes amplification of 
input chromatin before immunoprecipitation to demonstrate that equivalent amounts of 










GAPDH gene, which does not contain any p53-binding consensus sites were tested.  As 
anticipated, amplification using these negative control primers failed to demonstrate any 
enrichment for p53 binding neither before nor after Doxorubicin treatment (Figure 13).  
All of the other primer pairs (see Figure 12) that encompassed other potential p53 binding 
sequences failed to demonstrate any enrichment with doxorubicin treatment (data not 
shown).      
 Human YPEL3 induction inhibits cellular proliferation of tumor cells through 
induction of cellular senescence.  
Induced expression of exogenous YPEL3 results in a decrease in colony formation in 
breast and bone cancer cells.  
  
 As discussed previously, expression of exogenous murine YPEL3 has been 
shown by S. Baker to inhibit proliferation of mouse myeloid precursor cells (S. Baker, 
2003). This study demonstrated that 32Dcl3 myeloblastic cells stably expressing an 
inducible YPEL3 construct, resulted in a modest increase (~11%) in the detection of 
apoptotic cells evident in the YPEL3-induced cells compared to controls, as determined 
by Annexin V-based flow cytometry (see YPEL3 background section).  Considering the 
fact that mouse and human YPEL3 are 100% identical in amino acid composition, human 
YPEL3’s biological activity was assayed in human cell lines to determine if the growth 
suppressive phenotype observed in mouse was conserved in human cells.   The wildtype 
YPEL3 open reading frame (ORF) sequence was cloned into the pENTR-TOPO-D/SD 




Biosystems) as PCR template.  To facilitate lentiviral infection and controlled induction 
of YPEL3 expression in tumor and normal cell lines, LR-clonase-mediated transfer of the 
YPEL3 ORF from the pENTR shuttling vector into a lentiviral expression vector was 
performed.  This vector also contained a tetracycline operator (tet-on)-regulated CMV 
promoter to allow for regulated induction of YPEL3 expression and a C-terminal V5 
epitope tag to detect ectopic YPEL3 protein levels with anti-V5 antibody.  To allow for 
the creation of cell lines stably expressing YPEL3, this construct also confers resistance 
to the eukaryotic antibiotic Zeocin.     
                This expression system was tested in U2OS and MCF7 cell lines stably 
expressing the tetracycline repressor gene. Both cell lines were infected and then grown 
either with or without tetracycline for 14 days while under constant selection with 
Zeocin.  After this time had elapsed, a reduction in both the size and number of colonies 
formed by the YPEL3-expressing clones compared to those not stimulated by tetracycline 
to induce YPEL3 expression was evident in both cell lines tested (Figure 14A -C).  
Levels of YPEL3 mRNA reached just under 10 fold that of controls without addition of 
tetracycline (Figure 14C, top panel) which is well within the physiological range of 
expression normally seen downstream of p53 dependent activation in response to 
genotoxic stress (see Figures 2-5).  
                To further validate this anti-proliferative effect, a resazurin-based cell viability 
assay (CellQuanti-Blue™) was used to assess the effect that induction of YPEL3 had on 
cell viability.  The redox dye resazurin was added to cells that had been treated with 
tetracycline for 24h to induce YPEL3 expression.  This compound is internalized and 




Fluorescence can then be analyzed spectrophotometrically, providing a quantitative 
means to evaluate cell viability fluctuations resulting from induced expression of YPEL3.  
A decrease in the overall viability of cells induced to express YPEL3 compared to lacZ 
expressing controls was apparent after only twenty-four hours in tetracycline-containing 
media (Figure 14D).  This data provides compelling evidence that YPEL3 functions as a 
growth suppressive gene when expressed in human tumor cells.  After determining that 
YPEL3 expression in human cells caused a growth suppressive phenotype that was 
similar to that observed in mouse, it was of interest to determine the mechanism of this 
suppression.  However, after performing an extensive analysis to determine if YPEL3 
induction in human bone and breast tumor cell lines would result in apoptosis, there was 
no detectable difference in apoptotic induction indicated by caspase-3 dependent PARP 
cleavage and flow cytometry examining the apoptotic subG1 peak (data not shown).  It is 
still possible that murine YPEL3 (SUAP)-dependent programmed cell death observed by 
S. Baker is either species or cell type specific.  Further, endogenous mYPEL3 expression 
was also observed by S. Baker to be upregulated in response to interleukin-3 removal 
from mouse myeloblastic cells triggering differentiation into granulocytes and subsequent 
apoptosis.  This is an indication that YPEL3 may be involved in the regulation of normal 
hematopoiesis, including apoptotic turnover of mature granulocytes.  Furthermore, it is 
evident from reduced YPEL3 transcript levels in human hematologic tumors (Oncomine 
Microarray data, Figure 15) compared to normal bone marrow, that YPEL3 may play a 




Figure 14.  Induction of YPEL3 leads to growth suppression.  
 (A) Representative images of colony formation assays using MCF7TetR and U2OSTetR 
cells transduced with lentivirus containing a tet-inducible YPEL3-V5 cDNA, selected 
with Zeocin, and treated with and without 1 µg/mL Tetracycline (Tet).  (B) Histograms of 
average colony numbers from colony formation assays were repeated in duplicate 
(U2OSTetR) or triplicate (MCF7TetR).  Error bars represent the standard error of the 
mean.  (C) Top: Western blot demonstrating YPEL3 and LacZ protein expression in the 
indicated cell lines. Bottom: RT-PCR analysis of YPEL3 mRNA expression in 
MCF7TetR cells following treatment with tetracycline. (D) MTT assay of U2OSTetR 
cells transduced with the indicated lentivirus and then treated for 24 hours with or 
without tetracycline.  Each condition was performed in quadruplet with error bars 
representing standard error of the mean.  (Colony Formation Assay performed by Kelly 








.Figure 15.  YPEL3 expression is down-regulated in childhood leukemia tumors 
compared to normal bone marrow. 
Using Oncomine— an online repository of microarray data from various human tumor 
studies, as in silico YPEL3 gene expression analysis of 108 bone marrow and 13 
peripheral blood samples from patients with childhood acute leukemias was performed.  
The box plot depicts the relative expression of YPEL3 mRNA levels from each tumor 
type relative to unmatched normal bone marrow.  The top and bottom of each box 
represent the 75th and 25th or upper and lower quartiles, respectively. The transition 
between solid black to white in each box represents the median value of YPEL3 
expression.  The whiskers extend to the 90th and 10th percentile.  Filled dots show 
positions of highest and lowest outliers.  The number of patient samples for each 
condition is listed below (Oncomine Human Tumor Gene Expression Repository, 2009).  
N= number of patient samples for each tissue type 
B-cell Acute Lymphoblastic Leukemia, N = 87               
Acute Myeloid Leukemia, N = 23           
T-cell Acute Lymphoblastic Leukemia, N = 11   







suppression of hematologic tumor formation.  This was discovered while searching 
Oncomine—an online database containing microarray data for numerous human cancers, 
that acute myeloid leukemia, acute B-cell lymphoblastic leukemia, and acute T-cell 
lymphoblastic leukemia patient samples all demonstrate significant decreases in YPEL3 
gene expression compared to age-matched, normal bone marrow samples (Figure 15, 
Oncomine database) (Andersson,A., Ritz,C., et al. 2007, Rhodes,D.R., Kalyana-
Sundaram,S., et al. 2007).     Moreover, reduced YPEL3 expression may be involved in 
perpetuating a blast crisis considering the acute nature of some of the above tumors 
(Andersson,A., Ritz,C., et al. 2007).   
             In summary, apoptosis may not play a significant role in the YPEL3-dependent 
growth suppressive phenotype seen in colony formation and cell viability assays 
performed with human tumor cell lines by our laboratory. Nevertheless, there remains a 
possibility that YPEL3-dependent apoptosis induction may be cell lineage or tissue-type 
specific.  YPEL3 expression may play a role in hematopoietic regulation and possibly 
function as a myeloid lineage-specific tumor suppressor.   
YPEL3 expression induces a G1-cell cycle arrest.   
           After investigating the possibility that apoptosis was the cause of decreased 
proliferation of U2OS and MCF7 cells, other growth suppressive pathways in common 
with the p53 tumor suppressor pathway, such as cell cycle arrest and cellular senescence 
were considered.  In order to determine what effect YPEL3 has on the cell cycle, U2OS 
cells stably expressing a tet-inducible YPEL3 construct were induced to express YPEL3.   




cell cycle percentages were determined along with the percentage of apoptotic cells (sub-
G1 peak) for each condition.   An increase in the G1 population and decrease in S-phase 
cells was seen in cells expressing exogenous YPEL3 (Figure 16).  Thus, ectopic YPEL3 
expression in human tumor cells induces an arrest in the G1 phase of the cell cycle.   
YPEL3 induces premature cellular senescence. 
              Cellular senescence occurs when a cell enters an irreversible cell cycle arrest 
(Vousden,K.H. and Prives,C. 2009, Xue,W., Zender,L., et al. 2007).  This process can be 
triggered by a variety of stimuli such as telomere shortening after many rounds of DNA 
replication. This results in “replicative senescence,” a physiological process that occurs in  
“aged” cells after dividing a finite number of times before reaching telomere lengths that 
are prohibitive to carrying out further DNA replication.   Cellular stressors in the form of 
DNA damage, oxidative stress or oncogenic activation (i.e. ras-mediated senescence) can 
elicit a similar form of permanent cell cycle arrest termed “premature 
senescence.”(Fridman,A.L. and Tainsky,M.A. 2008)  Although detailed mechanisms of 
cellular senescence have not yet been completely determined, molecular pathways 
involved in cell cycle regulation such as the p53/CDKN1A  or Rb-regulated 
cyclin/CDK/p16 growth regulatory networks appear to be necessary to trigger and 
maintain senescence, respectively. (Fridman,A.L. and Tainsky,M.A. 2008).  To explore 
whether YPEL3 expression results in the induction of a senescent phenotype, a beta-
galactosidase staining11
                                                 
11 Accumulation of lysosomal beta -galactacdase is a common feature among senescent cells.  The amount of enzyme present can be 
assayed by treating cells with X-gal substrate under acid conditions.  This compound is processed by the enzyme to yield a blue 
colored product which will accumulate only in senescent cells, providing a means to identify these cells and measure this process in an 
experiment al population.    
 assay and senescence-associated heterochromatic foci detection 




Figure 16.  U2OS cells undergo a G1 arrest after induction of YPEL3 expression.  
Tet repressor expressing U2OS osteosarcoma cells stably expressing either 
tetracycline-inducible lacZ (negative control) or YPEL3 were induced for 5 days with 
1 μg/ml tetracycline.  Following treatment, cell cycle distribution, represented as the 
G1 / S phase ratio of each sample (top panel), was determined by propidium iodide 
staining followed by flow cytometry analysis and is represented graphically in the 
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Figure 17. YPEL3 expression triggers cellular senescence.  
  U20S cells stably expressing tet-inducible LacZ (left panel) as a negative control for 
senescence induction or tet- inducible YPEL3-V5 (right panel) were treated with 
tetracycline for 7 days and then stained Hoechst dye to visualize the nucleus and 
highlight senescence associated heterochromatin foci.  In addition cells were stained 
for senescence associated beta-galactosidase (bright field) which is identified by a 
cyan staining of the cytoplasm and nucleus.  The left panel represents the percentage 
of cells staining positive for beta-galactosidase activity.  The right demonstrates the 
percentage of nuclei containing heterochromatin foci.  One-hundred cells counted for 
each condition.  Error bars represent the standard error of the mean of three separate 

















seven days of ectopic YPEL3 induction (Figure 17).  It was observed in these cell lines 
expressing tet-inducible lenti-YPEL3 as well as in IMR90 normal human fibroblasts 
infected with lenti-YPEL3 (data not shown), that an increase in the percentage of beta-
Galactosidase positive cells was apparent compared to controls expressing only lacZ or 
GFP.   This data strongly supports a role for human YPEL3 in mediating cellular 
senescence.  This is currently thought to be the primary mechanism by which YPEL3 
induces a decrease in cell growth seen in colony formation assays.  Further, experiments 
have shown that endogenous YPEL3 is necessary for RAS-mediated senescence; a 
process that is also dependent on the functional p53 (Kelley, Miller, et al, 2010).  Even 
more surprising is the recent observation that ectopic YPEL3 expression can rescue the 
senescent phenotype in the presence of RNAi targeting p53 (Kelley, Miller, et al, 2010). 
Attenuation of endogenous YPEL3 expression results in a transient loss of contact 
inhibition in MCF10A cells. 
 
             With evidence that YPEL3 has growth suppressive properties when expressed in 
tumor lines, it is possible that YPEL3 may function as a tumor suppressor gene in vivo.  
Additional evidence for this tumor suppressive function stems from the analysis of 
YPEL3 mRNA expression levels in human ovarian tumors compared to normal tissue.  
Of the tumors sampled, YPEL3 expression levels were consistently lower compared to 
normal samples from the same patient (Kelley,K.D., Miller,K.R., et al. 2010).  This is an 
indication that these tumors may require lower levels of YPEL3 expression to transform 
and propagate efficiently.  Although this evidence is supportive of the classification of 




compromised by using either a shRNA based approach in cell lines or by knocking the 
gene out in mice are still required.   Of these two approaches, clearly the former is less 
expensive and labor intensive.  Therefore, the ex vivo approach was employed to acquire 
preliminary data that would justify investing in YPEL3-knockout mice.   
            By utilizing virally encoded shRNA targeting the YPEL3 gene, basal expression 
of YPEL3 was targeted in transformation-colony formation experiments using MCF10A 
cells.    The shRNA construct targeting hYPEL3 that is used in the following experiments 
has been validated for efficient knockdown (Kelley,K.D., Miller,K.R., et al. 2010).  
Although these cells are immortalized to facilitate continuous passaging in culture, they 
are not transformed and will normally stop growing when confluency is reached.  Thus, 
they normally grow to a complete monolayer before stopping cell division.  This 
monolayer is visualized in three  separate images five days after MCF10A cells were 
infected with GFP expressing virus at an MOI of 2.  Interestingly, compared to GFP-
infected cells, MCF10A cells infected with shRNA targeting YPEL3 demonstrate a loss 
of contact inhibition as some cells continue to grow above the monolayer (Figure 18, 
right panels).  They also have a reduced need for growth on the solid surface of culture 
plate because these cells, by nature of growing on top of the monolayer, have no 
substantial contact with the plate’s surface.  This phenotype was transient however. Ten 
days after transfection they die off and leave only cellular debris on the monolayer 
surface—a phenomenon seen in two independent experiments (Figure 19).  In summary, 
infection of MCF10A immortalized mammary epithelial cells with a shRNA construct 
targeting YPEL3 demonstrated a transient decrease in the contact / growth inhibitory 




could not be sustained under long term culturing conditions.   
            Most malignancies are thought to evolve over a period of time into more 
anaplastic states by accumulating a series of alterations in key cell cycle regulatory genes.  
This is illustrated by Nowell’s clonal tumor evolution hypothesis (see Introduction 
section), which emphasizes that the generation of increasingly neoplastic and aggressive 
clonal populations progressing towards “full-blown” oncogenic transformation results 
from individual clones—under selective pressure, accruing gain or loss of function 
mutations in oncogenes or tumor suppressor genes, respectively (Figure 20).  Many 
model systems exist that attempt to recreate and study this process of tumorigenesis in 
tissue culture settings.   
           The next experiment attempted to recapitulate this scenario in MCF10A cells, by 
targeting genes that regulate cell cycle homeostasis such as oncogenic RAS and p53 in 
the background of shRNA mediated reduction of YPEL3 gene expression.  The question 
was thus asked, would simultaneous attenuation of p53 expression with shRNA and 
oncogenic RAS overexpression be able to sustain shYPEL3 –dependent colony formation 
above the monolayer in MCF10A cells compared to infection of RAS and shp53 alone? 
To answer this question, MCF10A cells were virally infected with a triple combination of 
oncogenic RAS, shp53, and GFP (Figure 21 two images on the left) or oncogenic RAS, 




Figure 18. Reduced expression of YPEL3 decreases contact inhibition properties 
and solid support growth requirements of MCF10A immortalized mammary 
epithelial cells 
MCF10A immortalized mammary epithelial cells normally grow to a complete 
monolayer before stopping division.  This is evidenced by the three images in the left 
panel which show MCF10A cells infected 5 days earlier (MOI = 2).  Cells infected with 
shRNA targeting YPEL3 (MOI=2) demonstrate a loss of contact inhibition as they 
continue to grow above the monolayer.  They also have a reduced need for the solid 
surface matrix of the culture plate to support further growth.  These images are 







Figure 19.  The loss of contact inhibition afforded by shRNA mediated-reduction 
of YPEL3 expression is not maintainable in prolonged culture conditions. 
The image on the left is representative the GFP infected control population after 10 
days post-infection.  The image on the right displays complete loss of all cells with 
decreased contact inhibitive phenotype seen in figure 18.  Images are representative 








Figure 20. Nowell’s clonal tumor cell evolution hypothesis  
 The light and dark blue spheres represent cells that have been exposed to a DNA -
damaging event which results in genetic mutations.  Clonal expansion occurs until a 
second mutagenic event occurs which genetically alters the cell even further.  The 
product of these mutations is a phenotype more advantageous for cell growth and 
division compared to other clones in the population, allowing for positive selection of 
these clones.  Finally after several genomic insults the pre-neoplastic cell eventually 
acquires enough mutations that affect the regulation or expression of key tumor 









weeks.  Even after 10 days post-infection, cells infected with shYPEL3 (compared to 
GFP) showed significant colony formation above the confluent monolayer.   This pre-
transformed phenotype was indeed sustainable beyond 10 days in contrast to infection 
with shYPEL3 alone in Figures 18 and 19.  This experiment was performed twice over 
six weeks.  One set of plates was stopped  at two weeks and the other set of plates was 
stopped at four weeks of growth. In each case cells were stained with crystal 
violet/methanol stain to visualize colony formation and  revealed significantly more cell 
density on plates treated with shYPEL3, RAS and shp53 compared to RAS and shp53 
and control GFP virus at both time points (Figure 22).  Additional representative images 
of controls plates are also included to show that infecting cells with RAS or shp53 alone 
did not generate the same phenotype (see Figure 22).   Data generated from this 
experiment demonstrated that the reduction of YPEL3 expression by shRNA under 
conditions leading to the overexpression of oncogenic RAS and reduction of p53 
expression, were more advantageous to perpetuating a sustained phenotype where 
MCF10A cells lost contact inhibition and solid matrix requirements, than that observed in 
Figures 18 and 19 observed with only reduction of YPEL3 expression.  Although these 
data are very preliminary, these results are very encouraging and lay the foundation for 
future transformation experiments both ex vivo—performing soft agar / colony formation 
assays and in vivo— utilizing YPEL3 knockout mice to study the effect loss of YPEL3 





Figure 21.  Reduced YPEL3 expression along with both oncogenic RAS 
overexpression and reduction of endogenous p53 are sufficient to maintain a 
transformed phenotype in MCF10A immortalized mammary epithelial cells.  
The left panel shows two representative images from plates of MCF10A cells infected 
with lenti6-oncogenic RAS, lenti4-shp53, and lenti6-GFP 10 days post-induction.  
The right panel shows cells 10 days after infection with the same viral expression 
vectors (MOI=2) with the exception that lenti-GFP is replaced with lenti-shYPEL3.  








Figure 22. Reduction of YPEL3 gene expression in the presence of oncogenic RAS 
and reduced p53 results in increased colony formation in MCF10A immortalized 
mammary epithelial cells.   
Two and four weeks after infection with respective viral constructs with an MOI of 2, 
MCF10A cells were stained with crystal violet to demonstrate the degree of colony 
formation above the monolayer. Top panel: (above dotted line) Two weeks after infection 
cells were stained with crystal violet and photographed together.  Pairs of wells with 
black boxes around them are replicates and each pair was infected with the same viral 
constructs.  Bottom panel: (below dotted line)  The left plate was infected with RAS, 
shp53 and GFP.  The one of the right was infected with RAS, shp53 and shYPEL3.  Cells 
were allowed to grow for 4 weeks (media changed every 3 days) and then stained with 









 Prediction of a theoretical three-dimensional structure of the YPEL3 protein. 
 
           Since its completion in 2003, the human genome project has generated an 
immense amount of information characterizing the 23,299 protein-coding genes now 
annotated according to the Ensembl Gene Repository—a list that does not even include 
all gene variants derived from alternative splicing and ORFs.  This information is of little 
use, however to furthering basic scientific and biomedical research without structural / 
functional data regarding the protein products of these genes.   
 Characterization of a protein’s structure may provide hints to its function.  
Therefore, an attempt was made to computationally solve the protein structure of YPEL3 
from its primary amino acid sequence using two freely available structure prediction 
programs—Rosetta Ab Initio (Das,R. and Baker,D. 2008, Simons,K.T., Bonneau,R., et al. 
1999) (Figure 23) and I-TASSER Fold Recognition Server (Zhang,Y. 2008, Zhang,Y. 
2009) (Figure 24).   
 Rosetta ab initio is a protein structure prediction program available for download at 
http://www.rosettacommons.org/, and is freely available for academic use. The Rosetta ab 
initio structure prediction process relies heavily on C.B. Anfinsen’s seminal hypothesis 
that all proteins structures fold toward their lowest energetic state (Anfinsen,C.B. 1973). 
Applying this conjecture to the structural prediction of a hypothetical 100 amino acid 
protein, if it were possible to assess every possible structure for this protein, with each 
amino acid having on average, six degrees of freedom—the average representation of the 




Figure 23. The Rosetta ab initio protein structure prediction method  
The Rosetta ab initio protein folding method relies on the fact that proteins tend to fold 
into stable structures that decrease their thermodynamic free energy state (A and B).  The 
driving force for this is the burial of hydrophobic side chains (gray spheres) into the 
center of the structure along with the exclusion of water molecules from this region as 
shown by the folding of this “centroid” model where side chains are accounted for 
energetically as single spheres with discrete hydrophobic and electrostatic characteristics.   
The Rosetta algorithm uses Monte Carlo-based simulated annealing to computationally 
generate several thousand structural predictions.  (C) To select the best cluster of 
structures that is likely to resemble the true structure, the calculated energies of all 
predictions (Appendix, Table 1) are ranked and the group with the lowest energy score is 
selected.  This process is refined further by using an “all atom” energy algorithms 
(Appendix, Table 2) to minimize proposed structures toward the global energy minimum.   
Adapted from: DAS R., Baker D. (2008).  Macromolecular modeling with Rosetta.  Annu 








Figure 24.  The I-TASSER fold recognition server 
I-TASSER is a fold recognition and threading server that identifies primary sequence and 
secondary structure homologies between the query protein and protein data bank (PDB) 
structures. By following this protocol, primary and secondary structural information 
derived from the query protein’s amino acid sequence can be used to generate 
homologous matches to regions by overlaying or “threading” solved structural regions of 
proteins from the Protein Data Bank over the query sequence.  
Taken from: Zhang Y. (2009).  I-TASSER: Fully automated protein structure prediction in 
CASP8 Proteins 77 Suppl: 100-113.; Zhang Y. (2008). I-TASSER server for protein 3D 







 occupy the lowest possible free energy or “global energy minima.”   A protein such as 
the one described above would have 6^100 degrees of freedom, therefore, one obvious 
problem with structure prediction based solely on total energy calculations is that 
sampling all possible conformations that could occupy three-dimensional space is 
currently impossible even for relatively small proteins such as this one.  It is possible, 
however, to computationally sample through enough conformational space to arrive at an 
estimate that is reasonably close to the native structure.  To extend this logic further, the 
probability of arriving at a correct approximation of the native structure will increase 
proportionally to the amount of sampling performed (Das,R. and Baker,D. 2008).  A 
tremendous amount of computational resources are necessary to achieve even low 
resolution accuracy and also avoid common pitfalls such as getting “stuck” in a local 
energy minimum (Das,R. and Baker,D. 2008).  This commonly occurs from insufficient 
sampling and results in the generation of incorrect structural predictions that do not truly 
occupy the global energy minima but rather represent one of the many local minima that 
riddle the energy landscape.   With computational resources being limited, the accuracy 
of estimating a three-dimensional structure using ab initio –based calculations is 
primarily dependent on the number of sample structures generated (decoys).  This 
calculation is further impacted by a protein’s size being exponentially proportional to the 
number of structural confirmations possible (Das,R. and Baker,D. 2008, Simons,K.T., 
Bonneau,R., et al. 1999).   
 Based on the above reasoning, success using Rosetta has only been achieved 
solving relatively small proteins around 100 amino acids in size. These predictions have 




angstroms RMSD (Simons,K.T., Bonneau,R., et al. 1999).  These low resolution 
structures have been predicted by generating ensembles containing only a few thousand 
decoys and then choosing the cluster with the most neighbors and lowest energy using 
protocols similar to that used to predict YPEL3, briefly detailed next.   
 A Rosetta fragment library generator script along with the 119 amino acid YPEL3 
sequence as input was employed to generate fragments libraries containing either 3 or 9 
amino acid length fragments corresponding to parts of the YPEL3 primary sequence from 
parts of known structures with similar stretches of sequence derived from the RCSB 
Protein Data Bank.  These fragments libraries are assembled into potential structures 
termed decoys by a Monte Carlo based-annealing approach along with energy 
minimization perturbation protocols.  During this procedure, minimization involves using 
an energy score12
                                                 
12 An arbitrary thermodynamic estimation of the degree of effective hydrophobic burial of nonpolar side 
chains as well as the energy cost of polar side chain burial and hydrogen bond formation to compensate for 
this cost.  Solvation and long range electrostatic interactions are ignored which likely contribute to the high 
error (~10%) inherent with complex energy calculations. 
 to assess local chain perturbations or “moves” in each tertiary structure 
generated during the decoy generation and then accept or reject them based on 
Metropolis-based probability.  In other words, if the local energy score improves—the 
move is accepted.  If the “move” results in a higher (worse) energy score, this move is 
either accepted or rejected based on the degree to which the energy at a given simulation 
temperature is unfavorable (based on Boltzmann factor probability).  For prediction of 
YPEL3, a total of 50,000 decoys were generated over a period of 2 months using two 
computers running four processors each at 100% capacity.  From these, the decoys were 
ranked based on Rosetta energy score and the top 5,000 structures were clustered.   From 




representative centroid models from the best 10 clusters were selected for further 
analysis.   
 The second approach used to model YPEL3’s 3D structure was to submit the amino 
acid sequence for YPEL3 to the I-TASSER (Threading ASSEmbly Refinement) 
homology-based fold recognition server (Zhang,Y. 2008, Zhang,Y. 2009).  This is fully 
automated server only requires the user deposit the amino acid sequence of the protein of 
interest along with an e-mail address to return results to.  The server can be found at: 
http://zhanglab.ccmb.med.umich.edu/I-TASSER/.  The program begins by searching both 
primary and calculated secondary structures against the PDB library to find matches with 
>70% pair-wise similarity.  The program then “threads” the query sequence over 
matching folds from the database and the 3D coordinates of these folds are then exported 
and recombined to assemble a potential structure for the query sequence (Zhang,Y. 2008, 
Zhang,Y. 2009).  To refine this prediction further, energy minimization is then performed 
using a similar, though less exhaustive simulated annealing method used also in Rosetta 
ab initio, to model coordinates of connecting protein loops more precisely.   
The top 5 best structural predictions of YPEL3 were returned along with a predicted 
secondary structure and a structural alignment of the best 10 matches of the predicted 
YPEL3 structure with experimentally solved structures from the protein data bank 
(Figure 25).  These results will be discussed in the next section.      
Resulting structures generated for YPEL3 from each independent method of structural 
prediction converge on a similar fold. 





Figure 25.  I-TASSER fold recognition server structural prediction results for 
YPEL3.  
The I-TASSER automated server returned the top five predictions seen in the top panel 
below the YPEL3 query sequence which are relatively close in (alpha carbon trace) 







structure) with the I-TASSER YPEL3 prediction using UCSF Chimera Matchmaker 
(Pettersen,E.F., Goddard,T.D., et al. 2004) (Figure 26, purple structure), an alignment of 
35 atom pairs within a root mean square deviation (RMSD) of 3.9Å was evident when 
comparing both structures to each other; this similarity between structures is apparent by 
visual inspection especially surrounding the two pairs of cysteines on separate loops that 
fold to establish a metal coordination motif in both Rosetta ab initio and I-TASSER 
predictions (Figure 26, bottom panel).   Even more intriguing is the fact that an 
automated server called the ROBETTA Protein Prediction Server (Figure 27, white 
structure), which relies on the same code and energy calculations as Rosetta ab initio, 
generated a structure that aligned with the I-TASSER prediction (Figure 27, purple 
structure) even more precisely than comparisons observed between the Rosetta ab initio 
structure and I-TASSER prediction (see figure 26).  This may be due to the fact that 
Robetta performs an additional step to search for structural homology to the query 
sequence using PSI-BLAST and the Pfam database before generated 10K decoys and 
selected the lowest energy cluster.      
The predicted YPEL3 structure is structurally homologous with an enzyme involved in 
the oxidative stress response. 
             A search for solved protein structures with similarity to the YPEL3 predictions 
was performed next.   This search consistently returned homology matches with the zinc 
finger containing protein: Methionine-R-sulfoxide reductase from several prokaryotic 
species including Burkholderia pseudomallei (Figure 28), Methanothermobacter 
thermautotrophicus and Neisseria gonorrhea (see figure 25, bottom panel).  For example, 




Figure 26.  The Ab initio Rosetta and I-TASSER prediction models for YPEL3 
overlap within 3.5 Å for 35 /119 amino acids.   
The Ab initio Rosetta-predicted structure (yellow) was manually determined in eight 
weeks using two computers each containing a quad core processor.  Fifty-thousand 
decoys were produced and sorted to give only the top 5000 best predictions based on 
Rosetta energy calculations for each structure.  These structures were then clustered by 
structural similarity and the top 10 clusters with the most members and lowest energy 
were selected for further analysis.  After further minimization and idealization of bond 
lengths and torsion angels, the structure in yellow was generated (top, left structure). The 
I-TASSER prediction model in purple (top, right structure) was far less labor intensive to 
generate and much less computationally.  Bottom panel: Both structures were 
superimposed using University of California San Francisco's Chimera MatchMaker 
algorithm. They overlapped with each other within 3.5 Å for 35 /119 amino acids.  
Although this is only around 1/3 of the total protein it is important to point out that key 
structural motifs such as that the loops containing cysteines (highlighted in green) that 
make up a putative zinc finger motif align with a high degree of overlap in both 







Figure 27.  YPEL3 structures calculated with I-TASSER and the ROBETTA server 
align with a high degree of overlap.  
ROBETTA—the fully automated online version of the stand alone Rosetta code used to 
generate the structure in the previous figure, was used to predict YPEL3’s structure.  At 
the time of this work, there was a significantly long wait for ab initio structure prediction 
resources when trying to use ROBETTA.  This led to the YPEL3 structural prediction 
request sitting in queue for 6 months before being processed.  The prediction (white 
structure on the left) that was returned by ROBETTA however showed significant overlap 
with the I-TASSER prediction (purple structure on the right).  The RMSD between 
structures was 2.9 Å for 70 amino acid pairs determined from UCSF Chimera 








Figure 28.  The predicted YPEL3 structure is structurally homologous with an 
enzyme involved in the oxidative stress response.  
Top panel:  protein data bank repository crystal structure screen shot and structural 
characteristics of 3CEZ or Methionine-R-sulfoxide reductase.  Bottom Panel: two images 
of the superimposition between 3CEZ (orange structure) and the I-TASSER YPEL3 







Figure 29.  Structural homology between the I-TASSER predicted structure of 
YPEL3 and the crystal structure of  Methionine-R-sulfoxide reductase. 
 The Methionine-R-sulfoxide reductase crystal structure (3CEZ) is shown in blue (top, 
left) and the I-TASSER YPEL3 prediction is shown in purple (top, right)   
Superimposition of both structures reveals an RMSD of 3.2 Å between 78 (alpha carbon)      







Figure 30.  Structural homology between the Rosetta ab initio YPEL3 prediction 
and Methionine-R-sulfoxide reductase crystal structure  
The Rosetta ab initio structure (top, left) in yellow and Methionine-R-sulfoxide reductase 
crystal structure (top, right) in blue were superimposed in the bottom panel with Chimera 
MatchMaker with a RMSD of 4.1 Å between 34 amino acid pairs.  Cysteines that 








pseudomallei with the YPEL3 structural prediction from either I-TASSER (Figure 29) or 
Rosetta ab initio (Figure 30), revealed an alignment of 78 atom pairs with 3.2Å RMSD 
and 34 atom pairs at 4.1Å RMSD, respectively.   
 Methionine-R-sulfoxide reductase is involved in the oxidative stress response and 
functions to compensate for redox damage to proteins by reducing oxidized methionine 
(Etienne,F., Spector,D., et al. 2003).  There is also evidence that these enzymes may not 
just repair methionine residues but act to process and eliminate cellular reactive oxygen 
species (ROS)  pools by proxy through reducing susceptible methionines on affected 
proteins throughout the cell (Etienne,F., Spector,D., et al. 2003, Levine,R.L., Berlett,B.S., 
et al. 1999, Levine,R.L., Moskovitz,J., et al. 2000).  In other words, the availability of 
exposed methionines on the surface of cellular proteins makes up a large pool of reactants 
that could scavenge significant amounts of ROS.  The resulting product, methionine 
sulfoxide could then be reduced back to its native state by these reductases, and again be 
ready to accept more ROS if necessary.  Although enzymes that reduce methionine 
sulfoxide in mammalian cells have already been characterized, there may be more than 
one type enzyme that can accomplish this process and also establish redundancy for such 
an important process as the oxidative stress response.   This could implicate YPEL3 and 
its family members in mammalian cellular antioxidant processing and signaling; 
especially considering that YPEL3 is transcriptionally regulated by oxidative stress 
responsive genes such as p53.  Indeed, YPEL3’s role in mediating premature cellular 
senescence may also have some connection to upstream signaling, sensing or processing 
of oxidative damage by YPEL3 downstream of p53 transactivation.  Further because 




incentive to investigate YPEL3’s role in aging. 
 In summary, a model for the protein of structure of YPEL3 was generated by 
employing two independent structural prediction processes, the I-TASSER fold 
recognition program and Rosetta ab initio algorithm to generate two similar protein folds 
(Figure 31).  The most exciting aspect of the two predicted models is that they both 
converge on a similar structure even though each of the two prediction techniques relied 
on a different mechanism to solve YPEL3’s structure.  Furthermore, supporting that the 
process of manually solving YPEL3’s structure using Rosetta ab initio was done correctly 
and strengthening the probability of calculating a model similar to the native structure of 
YPEL3 is the fact that a third prediction program, ROBETTA—an automated version of 
Rosetta ab initio arrived at a similar prediction.  Moreover, this prediction aligns with the 
I-TASSER prediction with an even greater degree of precision than the Rosetta ab initio 
model.  Lastly, three-dimensional blast searches against known crystal structures within 
the PDB revealed homology between the computed YPEL3 model and a protein involved 
in physiological response to oxidative stress.  This implication along with YPEL3’s 
involvement in the regulation of senescence downstream of p53 (Kelley,K.D., 
Miller,K.R., et al. 2010) may reveal more about the mechanism of how YPEL3 functions 





Figure 31.  Summary of YPEL3 structure prediction using two separate 
computational prediction methods.   
Two relatively independent prediction algorithms, Rosetta ab initio and the I-TASSER 
fold recognition server were used to predict the three-dimensional structure for the 
YPEL3 protein.  Each prediction converged toward a similar structure as the other.  This 
structure has homology to the crystal structures of a family of prokaryotic 
oxidoreductases—the Methionine-R-sulfoxide reductases which are involved in the 









PART II  
 
FHIT is regulated through the AKT/ PI3K/FOXO3a pathway 
in response to mitogen depletion.   
 
INTRODUCTION TO PART II 
 
The FHIT Tumor Suppressor Gene  
 
              Fragile Histidine Triad, FHIT, is a 1.7 MB gene encoding a 16.8-kDa protein 
(Gatalica,Z., Lele,S.M., et al. 2000).  First identified in digestive tract cancers, FHIT gene 
expression was absent apparently as a result of deletions in the coding region of the gene 
(Ohta,M., Inoue,H., et al. 1999)(Smith,D.I., McAvoy,S., et al. 2007).  This finding 
provided the first clue that FHIT may have a tumor suppressive function.  It was 
subsequently determined that the location of the FHIT gene, 3p14.2, was located over one 
of the most common human fragile sites, the FRA3B locus (Ohta,M., Inoue,H., et al. 
1996).   Analysis of human lung cancer samples hinted at links between smoking, loss of 
FHIT expression, and lung tumor formation (Yanagisawa,K., Kondo,M., et al. 1996).  It 
was later discovered that the human FHIT gene was susceptible to mutation and loss of 
function from exposure to mutagens and carcinogenic compounds present in tobacco 
products (D'Agostini,F., Izzotti,A., et al. 2006, Pang,Y., Li,W., et al. 2008)(Pichiorri,F., 
Palumbo,T., et al. 2008, Smith,D.I., McAvoy,S., et al. 2007).  Double strand breakage is 




incomplete DNA replication at this site; breakage results in either complete loss of FHIT 
gene expression or reduction to levels which are not sufficient to maintain tumor 
suppressive function (Huebner,K. and Croce,C.M. 2001).  
             Aberrant FRA3B loci can be visualized by cytogenetic analysis of karyotypes 
isolated from many FHIT-null tumor samples which typically reveal chromosomal 
deletions or translocations involving these regions (Huebner,K. and Croce,C.M. 2001).    
Loss of FHIT expression by these mechanisms can result from chronic carcinogen 
exposure and has been shown to be one of the earliest events in lung cancer 
carcinogenesis (Herbst,R.S., Heymach,J.V., et al. 2008).   As such, diagnostic monitoring 
of FHIT expression levels in sputum samples has been proposed as a method for high 
throughput detection of early stage lung carcinoma (Li,R., Todd,N.W., et al. 2007).   
            The complete mechanism detailing how FHIT functions as a tumor suppressor has 
been unknown since the gene’s discovery over a decade ago.   It is currently know that 
FHIT functions enzymatically as a diadenosine triphosphate hydrolase; however, this 
activity was shown not to be necessary for onco-suppression (Campiglio,M., Bianchi,F., 
et al. 2006). In spite of this finding, enzymatic substrate binding was found to still be 
required for tumor suppression by FHIT.   This has been verified by experiments testing 
hydrolase and diadenosine triphosphate binding mutants for tumor suppressive function.  
The requirement for dinucleotide triphosphate binding may indicate that FHIT functions 
in signaling cascades similar to large heteromeric G-proteins which also bind nucleotide 
triphosphates upon activation of signaling (Trapasso,F., Krakowiak,A., et al. 2003).  It 
has also been demonstrated that FHIT is involved in the regulation of death receptor 




activation of intrinsic (mitochondrial) apoptotic pathways by interaction with Feredoxin 
reductase and concomitant generation of reactive oxygen species (ROS) resulting in the 
induction of programmed cell death (Trapasso,F., Pichiorri,F., et al. 2008).  
In addition to the biological link between FHIT expression and lung carcinogenisis, FHIT 
expression levels are reduced in certain types of breast cancer(Bianchi,F., Tagliabue,E., et 
al. 2007, Campiglio,M., Pekarsky,Y., et al. 1999, Gatalica,Z., Lele,S.M., et al. 2000, 
Guler,G., Uner,A., et al. 2004, Guler,G., Uner,A., et al. 2005, Huiping,C., Jonasson,J.G., 
et al. 2000, Iliopoulos,D., Guler,G., et al. 2005, Ingvarsson,S., Agnarsson,B.A., et al. 
1999, Ingvarsson,S., Sigbjornsdottir,B.I., et al. 2001, Tang,X.L., Yao,G.Y., et al. 2006, 
Wang,Z.B., Zhao,P., et al. 2006, Yang,Q., Nakamura,M., et al. 2002, Yang,Q., 
Yoshimura,G., et al. 2002, Zochbauer-Muller,S., Fong,K.M., et al. 2001).   For instance, 
FHIT has recently been shown to protect against HER2-driven breast tumor development.  
Loss of heterozygosity at the FHIT locus in breast tumors is associated with decreased 
patient survival and increased tumor burden (Bianchi,F., Tagliabue,E., et al. 2007).  
Moreover, reduced expression of FHIT has been shown to correlate with the expression 
of other fragile site-susceptible tumor suppressors such as WWOX in high grade-ductal 
carcinoma in situ (DCIS) breast cancers (Bianchi, F., et al,  2007).  In summary, FHIT is 
an important tumor suppressor gene whose functions are vital to inhibiting epithelial 
tumor formation (Figure 32).   
Rationale 
With the exception that exogenous E2F-1 (Ishii,H., Mimori,K., et al. 2004) can induce 





Figure 32. The FHIT tumor suppressor gene. 
FHIT and its role in suppression of tumor development have been extensively studied.  
Loss of FHIT occurs through expression of a common fragile site encompassed by the 
FHIT locus or through methylation of the FHIT promoter.   
Adapted from: Saldivar JC, Shibata H, Huebner K. Pathology and biology associated 







Adapted from: J Cell Biochem. 2010 Apr 1;109(5):858-65. Pathology and biology associated with the 
fragile FHIT gene and gene product. Saldivar JC, Shibata H, Huebner K. 




FHIT.  That is not to say that transcriptional regulation doesn’t play an important role in 
the loss of FHIT tumor suppressive function.  For example, there is evidence that 
epigenetic mechanisms of transcriptional silencing such as FHIT promoter 
hypermethylation contribute to the loss of FHIT expression and tumor progression 
(Goldberg,M., Rummelt,C., et al. 2006, Iliopoulos,D., Guler,G., et al. 2005, Wali,A., 
Srinivasan,R., et al. 2006, Yang,Q., Nakamura,M., et al. 2002, Zochbauer-Muller,S., 
Fong,K.M., et al. 2001). Surveys of FHIT expression in breast cancer tissue have 
revealed that 60-70% of tumor samples had strikingly reduced or no FHIT protein, and of 
these, only 30-35% contained aberrant transcripts resulting from purely genetic 
alterations (Bianchi,F., Tagliabue,E., et al. 2007).  Thus, the discrepancy between FHIT 
protein and aberrant transcript production is evidence for other causes of FHIT loss 
besides fragile site expression alone.  Further, the remaining breast tumors analyzed from 
the above study contained full length FHIT mRNA but at reduced levels compared to 
normal tissue, thus providing additional support for the existence of transcriptional modes 
of regulation of FHIT gene expression and emphasizing the importance of understanding 
how FHIT is regulated at the transcriptional level.  Lastly, little is known about how 
FHIT gene expression is regulated in dividing cells    
FHIT gene expression is upregulated after p53 activation by siRNA targeting HdmX 
and Hdm2.  
Revisiting microarray experiments performed to screen for new p53 target genes 
demonstrated that FHIT expression was elevated in MCF7 cells treated with siRNA 
targeting HdmX and Hdm2.  This observation was confirmed by qPCR (Figure 33).   
However, there was no decrease in FHIT mRNA levels as a result of lowering p53 




Figure 33.  RNAi targeting HdmX or Hdm2 leads to an increase in FHIT mRNA. 
 MCF7 cells were transfected with siRNAs targeting the indicated genes or a non-
targeting control (siCon). Total RNA was isolated 24 hours after transfection and p21 and 
FHIT mRNA levels were quantified by RT-PCR. The y-axis represents the relative 








  However, treatment with both siHdmX and sip53 did not result in an 
increase in FHIT expression seen with siHdmX alone.  This is an indication that the 
elevation of FHIT mRNA in response to siRNA-mediated HdmX depletion could be 
indirectly dependent on p53.  Considering these results, the next step was to determine if 
FHIT gene expression could be induced by p53 overexpression and DNA damage 
experiments.  The rationale for doing so can be found in the introductory section of this 
document regarding p53.    
FHIT is not a direct target of p53 
To further investigate whether FHIT was a direct target of p53, transient 
transfection of p53 into MCF7 cells was performed, but no increase in FHIT mRNA was 
observed 24 hours post-transfection (data not shown).  While interpreting this negative 
result, it was considered that post-translational modifications of p53 such as DNA 
damage dependent-phosphorylation (Riley,T., Sontag,E., et al. 2008) may be necessary to 
trigger p53 transactivation of FHIT gene expression. To test this, MCF7 cells were treated 
with a series of different DNA damaging agents to activate p53 through different DNA 
damage response pathways.   For example, Bleomycin was used because it can cause 
DNA double strand breakage similar to ionizing radiation and signals primarily through 
the ATM kinase damage response pathway to activate p53(Chen,J., Ghorai,M.K., et al. 
2008, Jazayeri,A., Falck,J., et al. 2006, Sun,Y., Xu,Y., et al. 2007).  On the other hand, 5-
fluorouracil (5-FU) binds and inhibits thymidylate synthase, and by doing so lowers 
thymine nucleotide reserves and inhibits DNA synthesis (Noordhuis,P., Holwerda,U., et 
al. 2004).  In addition, 5-FU can also activate p53 downstream of ribosomal stress 




Figure 34.  FHIT mRNA levels increase in response to bleomycin but not 
doxorubicin or 5-fluorouracil treatment. 
 76Ntert cells were treated with increasing doses of the radiomimetic bleomycin for 24h 
followed by RT-PCR analysis of FHIT, p21 and BAX treatment (left panel).  MCF7 cells 
were treated with 0.5µg/ml of doxorubicin for 24h and then p21 and FHIT mRNA levels 
were determined (top, right panel).  76nTert immortalized  mammary epithelial cells were 
treated with 1µg / ml of 5-fluorouracil for 24h followed by assessing p21 and FHIT 
mRNA levels (bottom, right panel).  All gene expression levels are normalized against 
their respective mock-treated control.  Error bars represent the 95% CI of three technical 







Figure 35. RNAi targeting Mdm2, MdmX and p53 is able to modulate PG13-luc 
luciferase activity. 
The PG13-luc luciferase reporter was used as control to measure changes in intracellular 
p53 activity. The promoter of this reporter contains a series of thirteen p53 consensus 
binding sites (top panel). MCF7 cells were transfected with siRNA for three consecutive 
days.  Twenty-four hours following siRNA  transfection, cells were cotransfected with  
PG13-luc  and Renilla-luc (Bottom panel).  Twenty-four hours post-transfection, whole 
cell lysates were assessed for luciferase activity.   Each sample was read in technical 







Figure 36.  The 5´ FHIT  promoter-luc does not demonstrate increased luciferase 
activity in response to RNAi targeting Mdm2, Mdm2 or p53  
The 5´ flanking region of the FHIT gene from -800 to +146, was cloned into the PGL3-
Basic luciferase reporter vector (top panel). MCF7 cells were transfected with siRNA  
targeting the indicated genes (x-axis) and after 24h subsequently cotransfected with FHIT 
promoter-luc and Renilla-luc.  Twenty-four hours post-transfection whole cell lysates 
were assessed for luciferase activity.  The error bars represent standard deviation of 







           After treatment of 76nTert and MCF7 cells, no increase in FHIT mRNA was 
observed in response to treatment with either 5-FU or doxorubicin (Figure 34, right 
panel).  Bleomycin treatment however, did result in up to a two-fold induction of FHIT 
mRNA (Figure 34, left panel).  This result was puzzling, however, because other types of 
previously mentioned DNA-damage did not result in such an increase.  It was considered 
that perhaps this was because only specific types of DNA damage were signaling through 
p53 to trigger an induction of FHIT gene expression at least in the case of ATM-
dependent signaling—resulting from double strand breaks caused by bleomycin but not 
from DNA damage caused by doxorubicin intercalation or 5-FU-induced ribosomal 
stress.  To determine whether or not the FHIT promoter contained a functional p53 
response element that may be responsible for increases in FHIT gene expression in 
response to DNA-double strand breakage, two regions of the FHIT promoter were cloned 
into the PGL3-BASIC luciferase reporter vector and tested in the presence of siRNA-
dependent reduction of HdmX and Hdm2 (Figure 35 and 36), and, p53, p63γ and p73α  
overexpression (Figure 38) or in the presence of p53 alone (Figure 37).  Each reporter 
contained at least 900 base pairs either upstream (5'-FHIT-luc) or downstream (3'-FHIT-
luc) of the FHIT transcription start site.  These regions were chosen because together they 
included two potential p53 binding motifs above a 60% threshold of similarity to the p53 
consensus binding site (data not shown).  None of the above treatments resulted in 
stimulation of either of the two FHIT luciferase reporters.  From these negative results 
generated from assessing the potential for p53 transactivation of the FHIT promoter, it 






FHIT gene expression is cell cycle dependent.  
 
 After examining  p53  as  a  possible  trans-acting  factor  responsible  for  
regulation  of  FHIT  gene  expression downstream of attenuation of Hdm2/X, other  
transcription factors  were  considered.  For example, exogenous  E2F-1  was  already  
known  to  bind  to  and  activate  transcription of   FHIT (Ishii,H., Mimori,K., et al. 
2004).  It has been reported that E2F-1 is negatively regulated by HdmX (Strachan,G.D., 
Jordan-Sciutto,K.L., et al. 2003, Wunderlich,M. and Berberich,S.J. 2002, Wunderlich,M., 
Ghosh,M., et al. 2004).    Therefore, cell synchronization experiments were conducted to 
determine if FHIT expression modulated in cell cycle specific patterns which could 
suggest a mode for E2F regulation.  Either aphidocolin (Figure 39) or nocodazole (Figure 
40) were used to synchronize MCF7 cells at the G1/S or G2/M phase of the cell cycle, 
respectively.   In the case of the aphidicolin treatment, once synchronized, cells were 
released into complete media and permitted to enter back into the cell cycle.   FHIT 
expression was monitored for changes in expression by collecting plates of at specific 
time points for protein and flow cytometric analysis by PI staining (Figure 39)   Cyclin  
A2 was used as a positive control for synchronization because its expression is typically 
elevated as cells progress from G1 into S phase.  It was apparent from Western blotting 
that FHIT expression decreased as cells progressed from G1 toward S and G2 phase.   
               In MCF7 cells treated with nocodazole to arrest cells in G2/M, followed by 





Figure 37.  The FHIT 5´ promoter does not contain any response elements to p53, 
p63γ, or p73α.   
The 5´FHIT- luc (top panel) was cotransfected into MCF7 cells with Renilla-luc and 
either p53, p63γ, or p73α expression vectors.  Extracts were assessed for luciferase 
activity 24h later and biological duplicates for each condition were averaged with error 







Figure 38. Exon 1 and the 5´ region of intron 1 do not contain any responsive p53 
binding sites.  
 A 1100 bp region further three prime of the sequence contained in the 5´FHIT-luc 
reporter was cloned into pGL3-Basic.  This reporter contained the first ~200 bp of the 
promoter region, exon 1 and part of intron 1 and is termed 3´FHIT-luc (top panel).  
MCF7 cells were cotransfected with Renilla-luc and either empty vector (PGL3-Basic), 
3´FHIT-luc, or 3´FHIT-luc + p53. Twenty-four hours post-transfection cells were lysed 
and extracts were assayed for luciferase activity relative to Renilla-luc activity to control 
for transfection efficiency (bottom panel).  Error bars represent standard error of the 








Figure 39.  FHIT protein expression decreases as MCF7 cells traverse the G1 / S 
phase boundary. 
MCF7 cells  were synchronized at the G1 / S  phase boundary by serum deprivation  for  
24h followed by treatment with complete media containing  1 µg / ml aphidicolin to 
temporarily block DNA polymerase.   Following a 24h incubation, cells were  rinsed 3X 
in PBS and released into complete media.  Cells were collected and assayed at the 
indicated times and assessed by flow cytometry (top panel) or  western blot (bottom  
panel) for FHIT protein levels as cells progress out of G1.  Also, cyclin A protein stability 







Figure 40.  FHIT mRNA expression increases as cells progress from G2/M back into 
the G1 phase of the cell cycle. 
MCF7 cells plated in T75 flasks were serum starved for 24 hours followed by release into 
complete media containing 4µM nocodazole for 16 hours.   Cells were rinsed 3X in PBS 
followed by release into complete media.  Flasks were vigorously vortexed horizontally 
for 30 seconds to release mitotic cells into media.  These cells were spun down in falcon 
tubes and stored on ice.  Using recycled media, this process was repeated 10 times, every 
5 minutes. Synchronized cells were re-plated on 6cm plates in complete media.  Cells 
were harvested every three hours for 18 h.  FHIT, cyclin A2, and cyclin D1 transcript 
levels were analyzed by RT-PCR (top panel).   Propidium Iodide staining and flow 
cytometry was performed on cells isolated at each time point to examine cell cycle 














into G1 phase.  Cyclin A2 mRNA levels went down and cyclin D1 mRNA levels 
increased which is typical of synchronized cells entering G1 (Figure 40).   
 Taken together, data from synchronization experiments releasing cells at 
different points in the cell cycle indicated that FHIT levels were highest when cells were 
in the G1 phase of the cell cycle compared to all other phases.  Furthermore, upregulation 
of FHIT mRNA and protein levels was verified after prolonged deprivation of serum and 
subsequent G1 arrest of MCF7 cells during synchronization protocols (see Figure 42). 
This finding was intriguing because it suggested a common mechanism for the 
modulation of FHIT expression.  It was hypothesized from these data that FHIT levels 
may be regulated based on position in the cell cycle.  In support of this, serum 
deprivation treatment and p53 activation after reduction of Hdm2/X expression 
(Heminger,K., Markey,M., et al. 2009)  both result in cells arresting in G1. Each of these 
treatments also leads to an increase in FHIT gene expression. Further, an elevation in 
FHIT expression as cells entered and progressed through G1 was observed from 
synchronization experiments (see Figures 39 and 40).     
   The pattern of FHIT expression in synchronized cells progressing through G1 
and into S phase of the cell cycle could be E2F-dependent based on reports of a 
functional E2F binding site in the promoter (Ishii,H., Mimori,K., et al. 2004).  However, 
upregulation of FHIT expression in serum starved cells argued against such a regulatory 
role because this treatment results in cells entering a quiescent state during which E2F is 
normally repressed by hypo-phosphorylated  Rb (van den Heuvel,S. and Dyson,N.J. 
2008).  Furthermore, although the inhibitory effect of HdmX on FHIT expression (see 




(Strachan,G.D., Jordan-Sciutto,K.L., et al. 2003, Wunderlich,M., Ghosh,M., et al. 2004) 
and subsequently driving transcription of FHIT, the same cannot be stated for the effects 
on FHIT expression seen in response to treatment with siRNA targeting Hdm2.  This is 
because Hdm2 leads to stabilization of E2F-1 by blocking its interaction with the E3 
ligase—Skp2 (Zhang,Z., Wang,H., et al. 2005).  This positive regulatory relationship 
would argue against E2F activation in response to siRNA mediated repression of Hdm2.  
However, to complicate matters even further, due to the high degree of homology 
between E2F family members’ consensus binding sites (Xu,X., Bieda,M., et al. 2007), it 
is possible that different E2F family members could bind to the same binding sequence 
and either repress (i.e. E2F-4-8) or activate transcription at this promoter region  (i.e. 
E2F-1-3)(Balciunaite,E., Spektor,A., et al. 2005, Conboy,C.M., Spyrou,C., et al. 2007).  
Thus it was possible that E2F-4-8 could have been involved in the repression of FHIT 
transcription during G2/M and S phase—when they are themselves not inhibited by 
p130/p107 pocket protein binding during G1 and thus would not be able to inhibit FHIT 
transcription (Balciunaite,E., Spektor,A., et al. 2005).    To alleviate these discrepancies, 
and determine if E2F factors play any role in the regulation of FHIT gene expression 
during the cell cycle, reporter analysis of the FHIT promoter containing an 
experimentally determined E2F binding site (Ishii,H., Mimori,K., et al. 2004) was carried 
out.    
The cell cycle dependency of FHIT gene expression does not involve E2F. 
   A luciferase reporter containing the 5´ FHIT promoter region encompassing a 
verified E2F consensus binding site (Ishii,H., Mimori,K., et al. 2004)  was cloned to test 




expression. To ensure  that  the  reporter  contained  a  functional  E2F  binding  site,  
cotransfection  of  both  the  FHIT-luc  reporter  and  E2F-1/DP-1 plasmids was 
performed and  resulted  in  a  two-fold  increase  in relative luminescence compared to 
cotransfection with a CMV vector control (Figure 41).  Moreover, a site-directed mutant 
reporter that contained a mutation in the E2F binding site abrogated this increase in 
luciferase activity in response to exogenous E2F-1/DP-1.   Following this validation, the 
construct was tested to determine if the presence of the E2F binding site would affect 
FHIT promoter activity in cycling cells by transfecting MCF-7 cells and subsequently 
serum depriving them (data not shown) or synchronizing them and performing a time 
course analysis.  Both conditions failed to stimulate an increase in FHIT-luc reporter 
luciferase activity.   This reporter was also previously tested in the presence of the same 
combinations of siRNA targeting Hdm2, HdmX and p53 used in the original microarray 
screening, however no difference in luciferase activity was seen when comparing 
siControl treated cells to those treated with siHdm2, siHdmX or sip53 (see Figure 36).    
It was concluded from the above data that E2F was not responsible for the elevation of 
FHIT gene expression seen in response to siRNA targeting Hdm2/X, serum deprivation 
or synchronization.     
Determining how FHIT gene expression is negatively regulated by growth factor 
receptor signaling. 
 
              Considering the  elevation  of  FHIT  levels  seen  upon  mitogen  removal  and  
subsequent  G1  arrest (Figures 42-44),  it  is  known that  activation  of  p53  through  




Figure 41.  The consensus E2F binding site contained  in the FHIT promoter is not 
required for modulation of FHIT expression  during cell cycle progression.  
(A) The CMV-luc reporter, expressing  the fire fly luciferase gene under the control of 
CMV promoter (left graph),  5´ FHIT-luc  containing a E2F consensus binding site 
(center graph), or the  5 ´ FHIT-luc reporter  containing a site-directed mutant E2F 
binding site  were each cotransfected with either empty vector (CMV) or a combination 
of E2F-1 and DP-1.  Luciferase expression was assayed 24 hours after transfection.   (B)  
The E2F binding site  is present in the wild type FHIT promoter  contained in wildtype 
5´FHIT - luc. Nucleotides changed by site directed mutagenesis to inhibit E2F binding to 
ΔE2F 5´ FHIT-luc  are shown in red.   (C)  FHIT 5´-luc or CMV-luc was transfected into 
MCF7 cells.  Following transfection, cells were serum starved for 24h and subsequently 
treated with 1 µg / ml  aphidicolin for 24 hours.  After release into complete media, cells 
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Figure 42.  FHIT expression increases in response to mitogen removal and 
subsequent G1 arrest in MCF7 cells.   
MCF7 cells were treated with serum containing media (0 h) or serum starved for either 
48 or 72 hours.  FHIT protein expression was determined by Western blotting (top panel, 
left) and RT-PCR (top panel, right) for each time point.  Cells from 0, 48 and 72h 
treatments were analyzed by flow cytometry to determine cell cycle distribution (bottom 















arrest  in  G1 (Heminger,K., Markey,M., et al. 2009).  Taken together with the 
observation that FHIT levels modulate as cells move into G1 from cell synchronization 
experiments (see Figures 39 and 40), expression of FHIT clearly appears to be regulated 
in a cell cycle-dependent manner.  It is still not known however, whether the effects seen 
on FHIT  expression as  a  result  of  synchronization, mitogen depletion or siRNA-
mediated activation of p53 are mediated by different factors or induced through the same 
mechanism.   
 To address the above issue further, a stepwise approach was taken in order to 
connect related pieces of data with current literature primarily focused on growth factor 
receptor signaling.  Data demonstrating that FHIT gene expression was elevated after the 
removal of mitogens was chosen as a starting point because this observation could be 
linked directly to what is currently known about mediators downstream of the growth 
factor receptor / mitogen complex.  Following validation of FHIT gene expression 
changes in response to serum deprivation, downstream mediators such as AKT and PIP3 
kinase were examined to determine if they were also involved in regulating FHIT gene 
expression downstream of growth factor stimulation.  With the aid of molecular pathway 
database analysis tools such as the Ingenuity Pathway Analysis (IPA) program (Ingenuity 
Systems, Redwood City, CA), other downstream intermediates were selected for 
additional analysis in order to “walk” down the most likely regulatory pathway.  For 
example, there are numerous factors regulated downstream of AKT/PIP3K which could 
be potentially involved in FHIT regulation (Figure 45).  By taking into account which 
factors are negatively and positively regulated by AKT, and which are transcription 




used to narrow the search for regulatory factors significantly.   Also, the biological 
function of FHIT, which is primarily growth suppressive, was taken into account when 
selecting factors upstream of FHIT that would most likely facilitate a growth suppressive 
phenotype.  To determine the effect of cellular entry into quiescence on FHIT gene 
expression, both normal and tumor cell lines were investigated to ensure that the original 
result regarding FHIT expression increasing after serum deprivation of MCF7 cells was 
not the result of a genetic deregulation inherent in this particular transformed cell line.  
Therefore, immortalized MCF10A mammary epithelial cells were deprived of mitogens 
and FHIT protein and mRNA levels were both observed to increase (Figure 44).  HCT116 
colon carcinoma cells also showed a similar increase in FHIT expression downstream of 
serum removal (Figure 43).   In conclusion, FHIT expression increases seen downstream 
of mitogen removal were not cell -type specific, as two additional cell lines demonstrated 
increases in FHIT expression after being deprived of growth factors.   
FHIT expression during growth factor depletion is dependent on PIP3 kinase 
dependent phosphorylation of AKT.   
 
                 The AKT/PIP3K complex functions downstream of many growth factor 
receptor families as second messenger kinases involved in transmitting pro-growth/ 
proliferation signals to the nucleus from growth factor receptors imbedded in the cell 
membrane (Manning,B.D. and Cantley,L.C. 2007).  To follow the mitogen responsive 
pathway downstream, PIP3K was examined to determine if repression of this kinase 





Figure 43.   HCT116 colon carcinoma cells demonstrate an increase in FHIT protein 
levels after being deprived of mitogens.  
 HCT116 cells expressing wtp53 were treated with and without 10% FBS for 48 hours.  
FHIT protein levels for each treatment condition were assessed by Western blot to reveal 
an increase in FHIT protein in cells deprived of serum compared to those in complete 







Figure 44 .  FHIT expression levels increase in response to mitogen removal  from  
MCF10A immortalized epithelial cells.  
MCF10A cells were treated with and without EGF present in culture media for 96 hours.  
FHIT protein (left) and mRNA levels (right) were assessed by Western blot and RT-PCR, 
respectively.  FHIT expression is shown to increase compared to levels in cells grown 









Figure 45.  The  AKT / PIP3K pathway 
AKT is phosphorylated by active PIP3K after growth factor receptor stimulation.  Acting 
as a second messenger, AKT transduces pro-growth signals by phosphorylating and either 
activating or suppressing oncogenic or tumor suppressive factors, respectively.    








  MCF7 cells were treated with the PIP3 kinase inhibitors wortmannin and 
caffeine each for 12 hours (Foukas,L.C., Daniele,N., et al. 2002, Hashimoto,T., He,Z., et 
al. 2004, Kong,D. and Yamori,T. 2008).    An increase in FHIT mRNA expression was 
observed 12 hours after treatment with both PIP3 kinase inhibitors (data not shown).  
Treatments with wortmannin (Figure 46) and an additional specific PIP3K inhibitor—LY-
294002 (Figure 47), were also performed by treating MCF7 cells with each drug for 
increasing amounts of time.  Cells were treated for a range of times (between 0 to 50 
hours) and resulted in time-dependent increases in FHIT mRNA expression under each 
treatment condition.  For each treatment condition, the amount of AKT phosphorylation 
was used to determine the degree of inhibition of PIP3K kinase activity by Western blots 
(Figure 46 and 47, bottom panels).  Also, cells treated with LY-294002 were examined for 
p27 and Gadd45a expression. Both of these genes are normally elevated in response to 
PI3K inhibition (Greenburg et al, 2002).     
Suppression of FHIT gene expression is dependent on AKT.  
 
                To verify that phosphorylation of AKT, a direct target of PI3 kinase activity, 
also decreased after serum deprivation, serum starved MCF7 cells were probed for AKT 
protein levels and compared to those from cells grown in 10% FBS (Figure 48).  As 
anticipated, total AKT protein stability was significantly reduced after removing growth 
factors and arresting cells for 48h (Figure 48, right panel).  Therefore it was possible that 
AKT could be regulating FHIT gene expression.  To further explore this mechanism of 
regulation, exogenous constitutively active AKT (ca-AKT) or kinase-dead AKT (KD-




Figure 46. Inhibition of PIP3 kinase activity with wortmannin leads to upregulation 
FHIT gene expression. 
MCF7 cells were treated with 1µM wortmannin, a specific inhibitor of PIP3 kinase 
activity for increasing amounts of time and then analyzed for FHIT mRNA expression. 
FHIT mRNA expression increases when normalized to the level of FHIT mRNA from the 
DMSO vehicle control (top panel).   AKT phosphorylation by PIP3K was used to 
determine the efficiency of PIP3K inhibition by wortmannin treatment.  A decrease in 
phosphorylation of AKT is noted in cells exposed to wortmannin for increasing amounts 







Figure 47. Inhibition of PIP3 kinase with LY-294002 leads to an upregulation FHIT 
gene expression. 
MCF7 cells were treated with 50µM LY-294002, a specific PIP3K inhibitor for increasing 
amounts of time and then analyzed for FHIT, p27 (top panel) and Gadd45a mRNA 
expression (center panel).   AKT phosphorylation by PIP3K was used to determine the 








Figure 48.  AKT protein stability decreases in MCF7 cells after mitogen removal.   
To determine the effect of mitogen removal on AKT expression, MCF7 cells were 
treated with serum free media for 48h.  Following treatment, protein extracts were 







Figure 49 . Constitutively active AKT partially impedes the serum deprivation-
dependent increase in FHIT expression normally seen after growth factor 
deprivation.  
In order to assess modulation of FHIT expression by AKT, MCF7 cells were 
transfected with expression plasmids encoding no protein (CMV), constitutively 
active AKT (CA-AKT) or kinase dead AKT (KD-AKT) prior to being serum deprived 
or remaining in complete media.  Cells were deprived of all growth factors for 72h 
















starved for 72h.  Analysis of FHIT mRNA levels by qPCR revealed that ca-AKT was able 
to partially13
Determination of trans-acting factor(s) responsible for mitogen depletion-dependent 
transactivation of FHIT downstream of PIP3K and AKT.   
  block—likely due to partial efficiency of transient transfection, the increase 
in FHIT mRNA normally seen in response to serum deprivation while the kinase dead 
mutant showed no inhibition of FHIT upregulation (Figure 49).  The results from both of 
these experiments provided support that FHIT is regulated by the PIP3K/AKT pathway 
downstream of growth factor receptor activity.   
                 Applying what is known regarding transcription factors regulated by AKT, the 
factors most likely to regulate tumor suppressive genes such as FHIT were selected for 
further analysis.  The Forkhead transcription factors or FOXO’s are a family of genes that 
have roles in aging, tumor suppression, cell cycle arrest and apoptosis (Arden,K.C. 2008, 
Dansen,T.B. and Burgering,B.M. 2008, Maiese,K., Chong,Z.Z., et al. 2009, Weidinger,C., 
Krause,K., et al. 2008).   They are homologues of the Daf-16 gene in C. elegans which is 
involved in aging and insulin signaling pathways (Huang,H. and Tindall,D.J. 2007).   
FOXO transcription factors are negatively regulated downstream of AKT by 
phosphorylation resulting in sequestration from the nucleus when the cell is actively 
involved in growth and cell division (Huang,H. and Tindall,D.J. 2007).  With the onset of 
growth arrest, such as during the absence of mitogenic stimulus, AKT is no longer active.  
FOXOs are thus no longer phosphorylated and are therefore able to enter into the nucleus 
                                                 
13 The efficiency of transient transfections are typically less than 100% which results in only a partial response to 




and transactivate stress-responsive target gene targets.  Notable FOXO target genes 
include KLF4, p27, p21, GADD45, BIM, FasL, and PUMA (Tran,H., Brunet,A., et al. 
2002, You,H., Pellegrini,M., et al. 2006, Yusuf,I., Kharas,M.G., et al. 2008, Zhu,S., 
Evans,S., et al. 2008). These genes have roles in tumor suppression either through cell 
cycle regulation through inhibition of cyclin dependent kinases (p27 and p21) and 
apoptosis (BIM and FasL) or are involved in DNA repair as is the case with 
GADD45(Huang,H. and Tindall,D.J. 2007).  Whether the FOXOs preferentially bind to 
and activate gene expression of apoptotic or cell cycle arrest and DNA repair genes is 
believed to be determined by the degree of FOXO acetylation which is controlled by the  
SIRT family of deacetylases (Giannakou,M.E. and Partridge,L. 2004, Huang,H. and 
Tindall,D.J. 2007, Wang,F., Nguyen,M., et al. 2007). 
                   Further support for FOXO regulation of FHIT stems from the observation 
that FHIT expression may modulate during the cell cycle.  FOXO protein stability 
increases downstream of the E3 ligase Skp2 during G1-S, so it is possible that FOXO 
could be contributing to the regulation of FHIT’s oscillatory behavior during the cell 
cycle (see Figure 39 and 40) (Dehan,E. and Pagano,M. 2005, Huang,H., Regan,K.M., et 
al. 2005).  Lastly, considering FHIT’s role in tumor suppression through cell cycle arrest 
and apoptosis (see FHIT background section), the FOXO transcription factors are ideal 
candidates for regulation of FHIT transcription downstream of the growth factor 
receptor/AKT/ PIP3 kinase pathway due to their tumor suppressive characteristics.   
                   To begin to examine if FOXO could be regulating the transcription of FHIT, 
the genomic DNA sequences up and downstream of the FHIT transcription start site were 




the beginning of the 1st intron (Figure 50).  Of these two potential binding sites, the 
sequence corresponding to the site furthest upstream was 100% conserved in both the 
mouse and human FHIT introns (Figure 51).   
Overexpression of the human FOXO transcription factor family leads to upregulation in 
FHIT mRNA and protein expression.   
                   To explore the possibility that FOXO transcription factors may be involved in 
FHIT regulation—FOXO1 TM, FOXO3a, FOXO3a TM14
 
, and FOXO4 were each 
overexpressed in MCF7 cells.  Exogenous expression of all four FOXO family members 
led to an increase in both FHIT mRNA and protein levels in cells analyzed 48h post-
transfection (Figure 52, FHIT mRNA and Figure 53, FHIT protein).   It was also of 
interest to determine if this increase in FHIT expression could be seen in a p53 –null cell 
line. This needed to be addressed based on earlier observations where FHIT increased in 
expression after siRNA targeting Hdm2/X in MCF7 cells. Therefore, the same FOXO 
overexpression experiments were repeated in SAOS-2 osteosarcoma cells followed by 
Western blotting for FHIT protein expression.  Although FHIT mRNA levels in these 
cells are lower than levels in breast and colon cells (RT-PCR data not shown), a 
detectable increase in FHIT protein is still evident in SAOS-2 cells overexpressing 
human FOXO family members compared to CMV transfected SAOS-2 cells (Figure 54).      
 
                                                 
14  The FOXOs denoted with TM (triple mutant) contain mutations in three 
serines that when phosphorylated by AKT, trigger nuclear export and therefore inhibit 




Figure 50.  Potential FOXO3a transcription factor binding sites within the FHIT 
promoter. 
Two FOXO binding sites were located in the first intron of the FHIT gene— 387 and 544 
bps downstream of the FHIT transcription start site, respectively.   Both sites had  >85% 







Figure 51.  FOXO3a consensus site 2 is conserved in mouse and human FHIT 
 intron 1. 
Using the University of California Santa Cruz Genome Browser to assess the degree of 
sequence homology between mammalian species, it was determined that FOXO3a core 
















FOXO-dependent upregulation of FHIT gene expression requires nuclear localization 
of FOXO.   
  To investigate whether modulation of FHIT expression in response to FOXO 
overexpression requires FOXO to actually enter the nucleus, an estrogen receptor (ER) –
FOXO3a fusion construct was expressed in MCF7 cells.  Nuclear import of the ER-
FOXO3a fusion protein can then be triggered after the addition of the partial estrogen 
agonist tamoxifen (4-OHT) (M. Greenberg., et al. 2002).  When ER binds to tamoxifen, 
translocation of activated ER into the nucleus occurs.  This particular estrogen receptor 
also contains mutations that make it resistant to the effects of endogenous estrogens so 
only tamoxifen can trigger nuclear localization.  This fusion construct will probe the 
dependence of FOXO directly transactivating FHIT based on the amount of time required 
to see increases in FHIT transcription after 4-OHT addition and determine if FOXO must 
also be in the nucleus for FHIT upregulation to occur.   
              MCF7 cells were infected with lentiviral FOXO3a TM-ER fusion expression 
construct described above.  Forty-eight hours after infection cells were treated with 1µM 
4-OHT for increasing amounts of time and analyzed by RT-PCR to measure changes in 
FHIT mRNA and Gadd45a mRNA (Figure 55).  As expected, both genes increased to the 
same degree after  4-OHT treatment.  Because FHIT mRNA levels modulate similarly to 
GADD45a—a known target of FOXO3a, this data provides further support that FHIT is a 
target of FOXO3a.  This experiment was repeated; with the exception that FHIT 
expression was analyzed after only two hours of 1 μM 4-OHT treatment and resulted in 
an increase in both FHIT and GADD45 mRNA (Figure 56).  Also as an additional 




lenti-FOXO3aTM-ER infected cells but failed to demonstrate any increase in FHIT or 
Gadd45a mRNA levels after two hours of 0.5μM 4-OHT treatment.  Because FHIT 
mRNA levels modulate similarly to GADD45a—a known target of FOXO3a, this data 
provides further support that FHIT is a direct target of FOXO3a.      
 Regulation of FHIT gene expression downstream of PIP3K is dependent on endogenous  
FOXO3a. 
 
                  To determine if upregulation of FHIT gene expression after chemical 
inhibition of PIP3K was dependent on FOXO transcription factors, MCF7 cells were 
infected and selected shRNA expression targeting either FOXO3a or FOXO1 and 
subsequently treated with wortmannin for 24h.   Although FHIT expression still increased 
downstream of PIP3K inhibition when FOXO1 expression was knocked down, no 
increase in either FHIT transcript (Figure 57) or protein levels (Figure 58) was apparent 
in cells that were stably expressing shRNA targeting FOXO3a.  This result, coupled with 
those seen after tamoxifen-inducible FOXO3a-ER nuclear localization, provide evidence 
that expression of the FHIT tumor suppressor gene is upregulated by the FOXO3a tumor 
suppressor after its release from oncogenic PIP3K/AKT signaling and cytoplasmic 
sequestration as cells enter a quiescent state in the absence of growth factor stimulation.    
Proposed mechanisms of cell cycle and HdmX and 2-mediated regulation of FHIT gene 
expression 
  
                    To address other modes of FHIT gene expression modulation in addition to 




are not only active during G1 arrest (Dansen,T.B. and Burgering,B.M. 2008, Huang,H. 
and Tindall,D.J. 2007) but their stability is also regulated in a cell cycle dependent 
manner by the E3 ligase Skp2 (Nakayama,K.I., Hatakeyama,S., et al. 2001).  This protein 
ubiquitinates FOXO as cells transition from G1 into S phase and effectively targets it to 
the proteosome (Dehan,E. and Pagano,M. 2005, Huang,H., Regan,K.M., et al. 2005).  
Thus as cells proceed through S phase it would be expected that the expression levels of 
FOXO transcriptional target genes would also decrease.  This could explain why FHIT 
levels drop after entry into S phase begins to increase again after completion of G2/M 
and reentry into G1.  
             Additionally, FOXO transcription factors are negatively regulated by Hdm2 and 
HdmX.  Hdm2 has been shown to act as an E3 ligase for all three mammalian FOXO 
transcription factors—targeting each to the proteosome for degradation (Brenkman,A.B., 
de Keizer,P.L., et al. 2008, Fu,W., Ma,Q., et al. 2009).  Further, HdmX has been shown to 
be stabilized after being phosphorylated at S367 by activated AKT.  This phosphorylation 
triggers C-terminal binding of the small scaffold protein 14-3-3. Furthermore, it is known 
that HdmX can facilitate stabilization of Hdm2 (Lopez-Pajares,V., Kim,M.M., et al. 
2008).  Moreover, Hdm2 is itself stabilized by AKT (Lopez-Pajares,V., Kim,M.M., et al. 
2008) as well as imported into the nucleus to ubiquitinate nuclear localized transcription 
factors such as p53 (Mayo,L.D. and Donner,D.B. 2001) and thus presumably FOXOs as 
well.  These AKT-dependent mechanisms of Hdm2 activation would be expected to 
promote the ubiquitination and proteosomal targeting FOXO transcription factors by 





Figure 52. FHIT mRNA expression increases in response to exogenous expression of 
the FOXO transcription factors 1, 3a and 4. 
MCF7 cells were transfected with either CMV empty vector, FLAG -FOXO1 TM (triple 
mutant), FLAG-FLAG-FOXO3a, FLAG-FOXO3a TM or FLAG-FOXO4.  Forty eight 
hours after transfection, cells were analyzed by RT-PCR to determine levels of FHIT 







Figure 53. FHIT protein expression increases in response exogenous expression of 
the FOXO transcription factors 1, 3a and 4. 
MCF7 cells were transfected with either CMV empty vector, FLAG -FOXO1 TM ,  
FLAG-FLAG-FOXO3a, FLAG-FOXO3a TM  or FLAG-FOXO4.  Forty eight hours after 
transfection, cells were lysed and 50µg of total protein from each transfection was 








Figure 54. FHIT protein expression increases in response to exogenous expression of 
the FOXO transcription factor family is p53 independent. 
p53-null SAOS-2 osteosarcoma cells were transiently transfected with either CMV empty 
vector, FLAG -FOXO1 TM ,  FLAG-FLAG-FOXO3a, FLAG-FOXO3a TM  or FLAG-
FOXO4.  Forty eight hours after transfection, cells were lysed and 50µg of total protein 
from each transfection was analyzed by SDS-PAGE and probed with indicated 
antibodies.  It is important to note that the FLAG antibody/ CMV lane contains a non-








 Figure 55. Nuclear localization of FOXO3a leads to an increase in FHIT transcript 
levels.  
A FOXO3a TM-estrogen receptor fusion construct was cloned and expressed in MCF7 
cells by lentiviral infection.  This fusion protein remains sequestered in the cytoplasm 
until tamoxifen (4OHT) is added to growth media (top panel).  Tamoxifen treatment 
allows FOXO3a-ER to enter the nucleus where it can affect the transcription of FOXO 
target genes.   Center panel: Expression of the Foxo3a-ER protein is detected by anti-rat 
HA antibody from H1299 protein extracts after infection, 7 days of Zeocin selection and 
subsequent analysis by Western blot in only 25% of clones screened due to FOXO-
associated cellular toxicity.  Bottom Panel: FOXO3a-ER infection of MCF7 cells 
followed by 4-OHT treatment 72h post-infection and RT-PCR analysis of FHIT and 
Gadd45a mRNA at the indicated time points after 4-OHT expression  demonstrate  FHIT 
levels increase in a comparable manner to Gadd45a—a known FOXO3a transcriptional 







 Figure 56. Nuclear import of FOXO3a results in FHIT and Gadd45a 
upregulation after two hours of 4-OHT treatment.    
Forty-eight hours after infection with either FOXO3a-ER or Control-ER virus each at a 
MOI of 3, cells were treated with 1µM 4-OHT for two hours.  An elevation of FHIT and 
Gadd45a  mRNA levels was evident in treated FOXO3a-ER expressing cells after 








Figure 57.  PIP3K-dependent suppression of FHIT transcription requires FOXO3a.  
MCF7 cells were infected with lenti-shRNA expression constructs targeting either 
FOXO1 or FOXO3a.   After treatment with 3µM wortmannin, RNA was extracted and 
analyzed for FHIT gene expression by RT-PCR.  Knockdown of FOXO1 had no effect on 
the increase of FHIT levels downstream of PIP3K inhibition.  However, attenuation of 
FOXO3a was able to completely block the increase in FHIT gene expression normally 
seen after wortmannin-dependent inhibition of PIP3K.  It is worth noting that endogenous 
expression of FOXO3a versus FOXO1 is significantly higher  in this cell line(>20 fold by 
RT-PCR analysis, data not shown).  This may explain why shRNA targeting FOXO3a 
results in such a dramatic effect compared to that of shFOXO1 on FHIT expression, even 








Figure 58. FHIT protein expression elevation after PIP3K inhibition is dependent on 
FOXO3a.   
MCF7 cells were infected with lenti-shRNA expression constructs targeting either 
FOXO1 or FOXO3a.  After selection, cells were treated with 3µM wortmannin for 24h.  









Figure 59. Proposed mechanism of regulation of FHIT gene expression by the AKT 
/PIP3K/ FOXO3a pathway.  
In dividing cells being stimulated with growth factor signals, PIP3K and AKT are 
actively transducing pro-growth signals.  AKT suppresses FOXO3a transactivation by 
phosphorylation of three key serine residues to keep it out of the nucleus.  In the event 
that the cell enters quiescence as a result of growth factor deprivation, FOXO3a can enter 
the nucleus and regulate transcription of grow suppressive target genes—one of which 

















destabilization as a result of siRNA mediated HdmX transcript reduction could also 
release FOXO factors from ubiquitination by Hdm2.  Thus, the increase in FHIT 
transcript levels seen in mircroarray experiments involving siRNA mediated knockdown 
of Hdm2 and HdmX may be explained through this mechanism.  
DISCUSSION 
             In summary, this project began with investigating the regulation of two genes 
derived from a microarray screen to search for new p53 targets. YPEL3 and FHIT gene 
expression were both shown to be upregulated downstream of p53 protein stabilization in 
a microarray screen that explored global gene expression modulation after RNAi-
mediated reduction of p53’s negative regulators, Hdm2 and HdmX.   Validation of 
YPEL3 as a novel p53 target gene was very straightforward.  All assays employed in 
characterizing YPEL3 revealed that it behaved exactly as a classic p53 transcriptional 
target.  The first section of this dissertation provided significant experimental evidence to 
validate this observation.  Genotoxic stress induced by treatment with DNA-damaging 
agents resulted in physiologic stabilization of p53 along with elevation of YPEL3 
transcript and protein levels.  Moreover, a cis-acting p53 response element within the 
YPEL3 promoter was identified and shown to be bound by p53 protein in response to 
genotoxic stress.  Finally, data was presented demonstrating that YPEL3 elicited growth 
inhibition of colony formation when expressed in tumor cells by causing these cells to 
senesce.  Similar growth suppressive phenotypes are typical of many other known p53 
target genes.  However, most of these genes are associated with the regulation of transient 
inhibition of cell division or the induction of apoptosis.  YPEL3 is unique in its ability to 




because it is among the first to play a role in this process.   
           To better understand YPEL3’s biological function and determine the mechanism of 
how YPEL3 induces cellular senescence, the second portion of this dissertation detailed 
the generation of a three-dimensional model of YPEL3’s protein structure.  It was 
hypothesized that predicting YPEL3’s protein structure may also aid in understanding the 
biological events involved in the induction and maintenance of premature senescence.  
Identifying structural homology between a predicted model of YPEL3 and other known 
structures may provide new insights into this process.  By using both the Rosetta ab initio 
and I-TASSER structural prediction algorithms, a likely three-dimensional structure of 
the YPEL3 protein was predicted which has significant structural homology to a family 
of Methionine oxidoreductases.  These enzymes catalyze redox-mediated antioxidant 
reactions which dissipate intracellular reactive oxygen species (ROS) through the repair 
of proteins damaged by ROS-mediated methionine to methionine sulfoxide oxidation.  
Based on this similarity, YPEL3 may play a role in the cell’s response to oxidative stress.  
Additionally, YPEL3 may normally function in the cell to quench reactive oxygen species 
(ROS) by reversing oxidized methionine sulfoxide back to its reduced state.  
Furthermore, as a p53 target, YPEL3 expression would be expected to be elevated in 
response to oxidative stress.  In the event that oxidative stress is severe, ROS-responsive 
proteins (i.e. YPEL3) may become overwhelmed and reach a saturation point.  As a 
result, these enzymes may not have the required reducing conditions necessary to 
regenerate back into an enzymatically functional state.  This could contribute to perhaps 
either conformational changes in protein structure or increased stability under prolonged 




investigation is necessary to assess potential roles YPEL3 may play in cellular 
senescence, oxidative stress and aging, collectively.   
           In the third part of this dissertation, FHIT, a tumor suppressor gene often deleted 
in epithelial-derived tumors, was also initially postulated to be regulated by p53.  FHIT, 
however was determined not to be a p53 target but rather a transcriptional target of 
FOXO3a—another tumor suppressive transcription factor (Figure 59).   Coincidentally, 
FOXO3a gene expression is induced under similar conditions as p53 such as cell cycle 
arrest, and certain types of genotoxic stress.  In support of this, FHIT transcript levels are 
elevated in response to the removal of mitogen-containing serum from breast, colon 
carcinoma, and immortalized mammary epithelial cells.   It has been demonstrated that 
expression of FHIT is suppressed by the AKT/PI3K pathway in cells stimulated by 
growth factor signaling.  These proto-oncogenic kinases phosphorylate and, thereby 
prevent FOXO3a from entering the nucleus.  Thus, FOXO3a is only able to enter the 
nucleus in the absence of mitogenic stimulation.  In other words, induction of FHIT gene 
expression is dependent on decreased PIP3K kinase activity and subsequent reduced AKT 
phosphorylation which occurs in the absence of growth factor stimulation.  As such, 
quiescence-dependent elevation of FHIT mRNA can be elicited independently of mitogen 
removal, by treatment with PI3K inhibitors, or attenuated by ectopic expression of 
constitutively active AKT during serum deprivation.  Further, ectopic expression of 
FOXO transcription factors results in the upregulation of FHIT mRNA and protein levels.  
FOXO must enter the nucleus for this modulation to occur. This is thought to be 
necessary based on the fact that FHIT mRNA levels do not modulate in the presence of 




to enter the nucleus.  Finally, experiments using shRNA targeting FOXO3a have revealed 
that the modulation of FHIT gene expression is dependent on endogenous FOXO3a 
expression levels.  
             This work provides vital insight into the molecular regulation of cell growth and 
proliferation by expanding our understanding of the transcriptional regulation of two 
important tumor suppressor genes.  This information has clinical applicability in that it 
has led to the identification of a new means to inhibit the growth of tumor cells— through 
which the expression YPEL3 can force these cells to senesce.  Also exciting is the fact 
that YPEL3 has been shown to be downregulated in human tumors and may thus be a 
potential tumor marker. 
 With respect to the FHIT tumor suppressor gene, there are currently more than 700 
publications investigating its role in cancer.  However, very little is known about how this 
gene’s expression is regulated.  It is now known that FHIT expression is normally kept 
low in dividing cells by activated PIP3K and AKT.  These oncogenic kinases indirectly 
suppress FHIT’s transcription by preventing FOXO3a from entering the nucleus.  It is 
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